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The objective of the dissertation was to assess 1) trends in prevalence of 
overweight and obesity among adolescents (12-19 years), 2) frequency and predictors of 
regular monitoring of metabolic parameters as recommended by the American Diabetes 
Association (ADA)/ American Psychiatric Association (APA) guidelines among 
adolescents, and 3) association of second-generation antipsychotics (SGAs) prescriptions 
with changes in weight, among adolescents  on antipsychotics compared to an age and 
gender matched randomly selected untreated comparison group. An ecologic study for 
the first objective and retrospective cohort studies for the second and third objective were 
conducted using a United States national electronic medical records database. Prevalence 
of overweight and obesity was assessed among exposed and comparison group 
adolescents during each calendar quarter between years 2000 and 2009. Frequency and 
predictors of regular monitoring of metabolic parameters were assessed in the second 
objective using multivariate logistic regression adjusting for covariates. Multivariate 
linear regression was used in the third objective to assess the percent change in follow-up 
body mass index (BMI) from baseline among antipsychotic users compared to the 
comparison group controlling for covariates. Adolescents on antipsychotics had higher 
prevalence of overweight and obesity than nonusing adolescents. The trend of prevalence 
of overweight and obesity among male antipsychotic users decreased while the trend of 





comparison group respectively.  The majority of adolescents on antipsychotics were 
under-monitored for BMI, lipids and glucose levels. Antipsychotic users with preexisting 
and newly diagnosed metabolic conditions were more likely to be regularly monitored for 
metabolic parameters than antipsychotic users without such conditions. Treatment with 
second-generation antipsychotics was associated with significant increase in BMI among 
adolescents relative to a matched comparison group. Antipsychotic treatment may have 
differential impact on weight gain in adolescent males and females. Strategies to increase 
awareness and adherence to ADA/APA guidelines in monitoring metabolic parameters 
among primary care physicians need to be developed. Weight gain among adolescents on 
antipsychotics needs to be controlled, or there may be increased use of limited health 
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Introduction of antipsychotics 
Antipsychotic agents are commonly used in the treatment of psychotic disorders, 
bipolar disorder, and nonpsychotic disorders. Clozapine was approved by United States 
Food and Drug Administration (FDA) for the treatment of schizophrenia in 1989, 
risperidone in 1993, olanzapine in 1996, quetiapine in 1997,1 aripiprazole in 2001. First 
generation antipsychotics (FGAs), shortly after their introduction, were shown to 
suppress the acute symptoms of psychotic disorders and prevent their recurrence.2 
However, many patients with chronic disorders were found to be unresponsive to these 
antipsychotic drugs. In general, these drugs were found to be inadequate in affecting the 
long-term course of psychotic disorders and in improving outcomes.3 Moreover, FGAs 
have been found to be associated with neurological disorders, such as acute 
extrapyramidal side effects (EPS) and tardive dyskinesia (TD).4 The picture started to 
change with the advent of the second-generation antipsychotics (SGAs).  This class of 
drugs is understood to have a significantly lower risk of the above-mentioned side 





Although SGAs are associated with relatively lower side effects, they have been 
noted for their potential of causing metabolic disturbances including obesity, 
dyslipidemia and diabetes, leading to metabolic syndrome.6 Cardiometabolic adverse 
effects in adolescents and children are of concern during development because they 
increase the risk of adult obesity, the metabolic syndrome, cardiovascular morbidity, and 
possibly malignancy.7-10 Weight gain as a result of antipsychotic medications can cause a 
particular problem in these adolescents since their self-esteem is already decreased due to 
coping with their mental illness, and weight gain can make that worse.11 Weight gain is 
not only an issue of self-esteem; it can also create an increased risk of hypertension, 
coronary artery disease, stroke, gallbladder disease, osteoarthritis, sleep apnea, 




Prevalence of antipsychotic use in children and adolescents 
Antipsychotic medications are increasingly prescribed to children and adolescents 
in the United States as first line treatment for psychotic disorders, bipolar disorder, and 
nonpsychotic mental disorders.12 A study conducted by Curtis et al. estimated the 1 year 
prevalence of atypical antipsychotic use by age and sex among commercially insured 
youths in the United States.13 The authors reported that the annual prevalence of atypical 
antipsychotic use was 267.1 per 100,000 patients aged 19 years and younger. Compared 
to the total population, patients with at least one claim for an atypical antipsychotic were 
more likely to be male (71% vs. 51.2%, p<0.001) and were older (76.9% vs. 51.6% of 





was nearly 3.5 times higher in boys than in girls. More than 25% of male patients with at 
least one prescription for antipsychotic were aged 9 years or younger.  
Another study examined changes in the prevalence of antipsychotic medication 
use and the characteristic of antipsychotic users in the US population between 1996 and 
20051. According to the authors, SGA use has increased between 1996 and 2005. The 
population prevalence of SGA use increased almost sevenfold in 8 years; 0.15% of the 
population used SGAs in 1996-1997 compared to 1.06% in 2004-2005. A study 
conducted by Olfson et al. examined national trends and patterns in antipsychotic 
treatment of youth seen by physicians in office-based medical practice.12 According to 
the authors, the estimated number of office-based visits by youth that included 
antipsychotic treatment increased from approximately 201,000 in 1993 to 1,224,000 in 
2002. The number of visits that included antipsychotic treatment was significantly higher 
for male white non-Hispanic youth. Overall, 9.2% of mental health visits and 18.3% of 
visits to psychiatrists included antipsychotic treatment. From 2000 to 2002, 92.3% of 
visits with prescription of an antipsychotic included second-generation medication. The 
authors concluded that there was a sharp national increase in antipsychotic treatment 
among children and adolescents in office-based medical practice. A recently published 
study found that American children take antipsychotic medicines at about six times the 
rate of children in the United Kingdom.14 The overall prevalence of use of all 
antipsychotics almost doubled from 0.39 to 0.77 users per 1000 patient years for patients 
0 to 18 years of age. These results demonstrated a very different picture from the study 
by Olfson et al.12 in the United States, which showed a six fold increase in antipsychotic 





Antipsychotics and weight gain 
Although SGAs are associated with relatively smaller number of side effects they 
have been noted for their potential of causing metabolic disturbances including obesity, 
dyslipidemia and diabetes.11, 15, 16 Published clinical trials suggest an increased risk of 
weight gain among both preadolescent and adolescent populations, as a result of SGAs.15, 
16  Weight gain as a result of antipsychotic medications can cause a particular problem in 
these adolescents since their self-esteem is already decreased due to coping with their 
mental illness and weight gain can make that worse.11  Only two observational studies 
have assessed the association between antipsychotics and weight gain among adolescents 
and children. The first study, a retrospective cohort study, evaluated Medicaid medical 
and pharmacy claims to identify factors associated with incident cardiovascular events 
and metabolic disturbance in children and adolescents treated with antipsychotics.17 The 
study found that antipsychotic treatment was associated with 2.13 times increased 
likelihood of obesity (odds ratio [OR], 2.13), compared to the untreated cohort. One of 
the limitations of this study is the limited generalizability of South Carolina’s Medicaid 
enrollees to the US population as the Medicaid population is usually sicker in general 
with more comorbidities than the commercially insured population.18 The limitation of 
this study is that the actual impact of antipsychotic treatment on clinical values was not 
known from this study. The second observational study was a prospective cohort study 
conducted in 203 youths aged 4 to 19 years with 1 week or less of lifetime antipsychotic 
treatment assessed the association of SGA medications with body composition and 
metabolic parameters.19 After a median of 10.8 weeks treatment with SGAs researchers 





quetiapine, by 5.3kg with risperidone, and by 4.4 kg with aripiprazole compared with 
minimal weight change of 0.2 kg  in the untreated comparison group. Limitations of this 
study included the short duration of treatment (12 weeks), small comparison group 
(n=20), and limited generalizability of results to the national population. The study 
reported absolute change in BMI from baseline to 12 weeks of treatment without 
adjusting for or matching the comparison group to the treatment group by gender. 




Monitoring of metabolic parameters 
Guidelines published by the American Diabetic Association (ADA)/ American 
Psychiatric Association (APA) recommend monitoring of patients on antipsychotics 
regularly. 6 An eight member panel developed these guidelines based on evidence from 
experts drawn from the areas of psychiatry, obesity, and diabetes including 
representatives from the United States Food and Drug Administration (FDA) and the 
pharmaceutical industry.6 The ADA/APA guidelines recommend monitoring BMI at 
baseline, then at 4, 8, 12 weeks, and quarterly after initiating or changing atypical 
therapy. Blood pressure and fasting plasma glucose should be checked at baseline, 12 
weeks, and then annually. Fasting lipid profile should be checked at baseline, 12 weeks, 
and then every 5 years if normal. A check of total triglycerides and cholesterol every 
three months during the first year of atypical use has also been suggested. In 2004, the 
FDA required all manufacturers of SGAs (atypical antipsychotics), such as Clozaril ® 
(clozapine), Risperdal ® (risperidone), Zyprexa ® (olanzapine), Seroquel ® (quetiapine), 





labels about the increased risk of hyperglycemia and diabetes.20 In 2010, the FDA 
changed prescribing information for olanzapine, with recommendations that physicians 
consider the increased potential for weight gain, hyperlipidemia, and long-term risks in 




Public health implications 
The public health implications of pediatric and adolescent patients on 
antipsychotic drugs and its associated cardiometabolic adverse effects are substantial. At 
present, obesity is a serious health concern among all adolescents and children. Published 
studies using data from NHANES surveys (1976–1980 and 2003–2006) show that the 
prevalence of obesity for children aged 2–5 years increased from 5.0% to 12.4%. 
Prevalence of obesity for those aged 6–11 years increased from 6.5% to 17.0% and for 
those aged 12–19 years, prevalence increased from 5.0% to 17.6%.22, 23 Children and 
adolescents who are obese are more likely to remain obese as adults.24 A study published 
by Whitaker et al. found that approximately 80% of children who were overweight at 
aged 10–15 years were obese adults at age 25 years.24 Another study found that 25% of 
obese adults were overweight as children.25 The latter study also found that if overweight 
begins before 8 years of age, obesity in adulthood is likely to be more severe.  
The costs of obesity, for the year 2000, in the United States were estimated at 
$117 million – $61 million due to direct healthcare costs (i.e., preventive, diagnostic, and 
treatment services for obesity and related diseases) and $56 million on indirect costs (i.e., 
wages lost because of illness or disability, and future earnings lost because of premature 





diseases has increased more than threefold, from $35 million in 1979-1981, to $127 
million in 1997-1999.27  
There are numerous factors that contribute towards childhood obesity. Published 
evidence shows that antipsychotic treatment in children and adolescents may be 
associated with cardiometabolic factors. Physicians need to do a careful cardiometabolic 
evaluation prior to prescribing antipsychotic medication in pediatric and adolescent 
populations. Also, there is need for regular monitoring and evaluation of cardiometabolic 
adverse effects in this population. Findings from the current study may be used to create 
awareness and educate physicians about the need for monitoring of metabolic parameters 
and the risk of weight gain in adolescent patients who are prescribed antipsychotics to 




Gaps in literature 
Treatment-associated weight gain, coupled with increased antipsychotic 
prescribing among adolescents in the United States, may impact the prevalence of 
overweight adolescents. There is a significant gap in the literature and no studies to date 
have assessed the trend of prevalence of overweight among adolescents stratified on 
antipsychotics use. Previous studies have addressed the short term impact , 12 weeks to 1 
year, of antipsychotic treatment on weight gain. However, none of the studies have 
addressed the long term trend of weight gain over 10 years due to antipsychotic treatment 
adjusting for increasing trend of weight among normal adolescents. The results of this 
study will provide an estimate of the seriousness of the problem of obesity among 





Secondly, very little information exists in the literature regarding the monitoring 
of metabolic parameters in the national population with commercial insurance treated in a 
primary care setting. Most importantly, none of the studies to date have assessed the 
monitoring of BMI and blood pressure, specifically in adolescents on antipsychotics. The 
ADA/APA guidelines suggest that physicians need to do a careful review of baseline 
metabolic parameters before or as soon as initiating antipsychotic treatment. Previous 
studies have assessed the monitoring patterns of metabolic parameters among adults on 
antipsychotics, which have been relatively low in commercially insured populations.28, 29 
A study conducted by Haupt et al. in commercially insured adults found that 9% and 17% 
received lipid and glucose testing within 12 weeks of starting SGA medication.28 Another 
study by Morrato et al. conducted using administrative data from two managed care plans 
reported that only 13% of adults had glucose and lipid testing within 6 months of starting 
antipsychotic medication.29 The findings from a study conducted in veterans reported 
relatively better monitoring rates of 39% for lipids and 57% for glucose testing 
respectively within 6 months of initiating SGA therapy.30 Only one study assessed the 
monitoring of metabolic parameters using Medicaid data specifically among adolescents. 
The authors reported that lipid and glucose testing was performed in 13% and 32% of 
children and adolescents occurring 30 days before through 180 days after initiating SGA 
treatment.31 The results of this study may not be generalizable to the national population 
as the Medicaid population is usually sicker with more comorbidities than the 
commercially insured population.18 None of the studies conducted in adolescents have 
assessed the monitoring of metabolic parameters prior to initiating antipsychotic 





monitoring of metabolic parameters in adolescents treated with SGAs. It remains 
unknown whether demographic characteristics, insurance type, concomitant medication 
use, and baseline medical conditions in addition to antipsychotic use are associated with 
regular monitoring of metabolic parameters among adolescents. There are limited 
retrospective studies comparing the differential risk of weight gain associated with SGAs 
in the adolescent population. The observational studies that have been conducted so far 
have either used short duration of treatment or a small comparison group. A real world  
study that assesses the differential impact of SGAs on weight gain in adolescent 
population is warranted. The goal of the current study is to compare the change in BMI 
among adolescents within 1 year of initiating antipsychotic treatment to the change in 












First Generation Antipsychotics (FGAs) Second Generation Antipsychotics (SGAs) 
Prochlorperazine (Compazine)*  Olanzapine (Zyprexa) 
Haloperidol (Haldol) Quetiapine (Seroquel) 
Thioridazine (Mellaril) Aripiprazole (Abilify) 
Chlorpromazine (Thorazine) Risperidone (Risperdal) 
Perphenazine (Trilafon) Ziprasidone (Geodon) 
Fluphenazine (Prolixin) Paliperidone (Invega) 
Thiothixene (Navane) Iloperidone (Fanapt) 




Mesoridazine (Serentil)  
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Objective: To assess the trends in prevalence of overweight and obese among 
adolescents on antipsychotics compared to nonusing adolescents.  Design: An ecologic 
study of calendar quarters from 2000–2009 was conducted using an electronic medical 
records database. Setting: Outpatient, primary care. Main Exposure: The exposure 
group included 13,552 observations contributed by male and female adolescents on 
antipsychotics over 38 calendar quarters while the comparison group consisted of 40,659 
patients randomly age- and gender- matched (3:1) to the exposed group. Outcome 
Measures: The primary outcome variable was the prevalence of exposed and comparison 
group patients during each calendar quarter between years 2000 and 2009. Prevalence 
was defined as the proportion of exposed and comparison group patients with body mass 
index (BMI) at or above the 85th or 95th percentile, as defined by age- and gender-specific 
growth charts, over total number of exposed and comparison group in each calendar 
quarter. Results: The mean BMI of exposed males and females during the overall study 
period was significantly higher (25.99 and 27.48 kg/m2) compared to the comparison 
group (24.43 and 25.14 kg/m2) (p<0.001). The mean prevalence of overweight among 
exposed males (38.83% vs. 26.57%) and females (34.54% vs. 20.81%) was also 
significantly higher than the comparison group during the study period (p<0.01). 
Quarterly trend analysis indicated significant differences in prevalence between exposed 
and comparison group males for age-adjusted BMI ≥85 and ≥95 percentile (p<0.01) and 
age-adjusted BMI ≥95 percentile among females (p<0.05) from 2000 to 2009. 
Conclusion: Overall, adolescents on antipsychotics had higher prevalence of overweight 





and female antipsychotic users was higher compared to the nonusing male and female 
adolescents. The trend of prevalence of overweight and obese among male antipsychotic 
users decreased while the trend of prevalence increased for male nonusing adolescents. 
On the contrary, the trend of prevalence of overweight and obese among female 
antipsychotic users increased while the prevalence remained stable among female 





The number of children who take medications for chronic diseases has increased 
dramatically in the United States in recent years.1-3 Evidence suggests that the prevalence 
of metabolic syndrome phenotype among US adolescents increased from 4.2% in 1988-
1992 to 6.4% in 1999-2000.4     The prevalence of obesity increased significantly from 
13.8% in 1999-2000 to 16.0% in 2003-2004.5  There has been a sharp national increase in 
antipsychotic treatment prescribed for psychotic disorders, bipolar disorder, and 
nonpsychotic mental disorders in children and adolescents in the United States. 3 A study 
by Olfson et al. examining national trends and patterns in antipsychotic treatment of 
youth reported that 9.2% of mental health visits and 18.3% of visits to psychiatrists 
included antipsychotic treatment.  From 2000 to 2002, 92.3% of visits with prescription 
of an antipsychotic included a second-generation antipsychotic (SGA).3 The annual 
prevalence of SGA use was reported as 267.1 per 100,000 patients aged 19 years and 
younger. Published clinical trials point towards an increased risk of weight gain among 
both preadolescent and adolescent populations, as a result of SGAs.6, 7 Previous studies 





However, none of the studies have addressed the long term trend of weight gain due to 
antipsychotic treatment adjusting for increasing trend of weight among normal 
adolescents. Weight gain in youth is not only an issue of self-esteem; it can also create an 
increased risk of hypertension, coronary artery disease, stroke, gallbladder disease, 
osteoarthritis, sleep apnea, respiratory problems, cancer, type II diabetes and 
hyperlipidemia.8  
The public health implications of children and adolescent patients on 
antipsychotic drugs and its associated cardiometabolic adverse effects are substantial. At 
present obesity is a serious health concern among adolescents and children and 
antipsychotic use may exacerbate this problem. Published studies indicate that from 
1976–1980 to 2003–2006, respectively, the prevalence of obesity for children aged 2–5 
years increased from 5.0% to 12.4%, 6–11 years increased from 6.5% to 17.0%, and 12–
19 years increased from 5.0% to 17.6%.9, 10 The costs of obesity, for the year 2000, in the 
United States were estimated at $117 million – $61 million due to direct healthcare costs 
and $56 million in indirect costs.11 Among children and adolescents, the annual cost of 
treating obesity-related diseases has increased more than threefold, from $35 million in 
1979–1981, to $127 million in 1997–1999.12  
Treatment-associated weight gain, coupled with increased antipsychotic 
prescribing among adolescents in the United States, may impact the prevalence of 
overweight adolescents. There is a significant gap in the literature and none of the studies 
to date have assessed the trend of prevalence of overweight among adolescents with or 
without antipsychotics. We hypothesized that increase in the prevalence of antipsychotic 





compared to those not treated with antipsychotics overall and across time. The purpose of 
the study is to assess the overall and quarterly trends of prevalence of overweight and 
obese adolescents on antipsychotics compared to a stratified random matched comparison 






The General Electric (GE) Centricity electronic medical record (EMR) database 
was used for this study. The GE EMR database has data on approximately ten million 
patients. The GE EMR database is comprised of data submitted by more than 70 
consortium member institutions located in more than 40 states. A variety of practice types 
are represented ranging from solo practitioners to community clinics, to academic 
medical centers and large integrated delivery networks. The resulting research database 
provides information reflective of the clinical data captured in the practice setting, 
including diagnoses, chief complaints, medication orders, medication lists (patient-
reported prescription and over-the-counter drug use), laboratory orders and results, and 
biometric readings. Using this database, patients on antipsychotic treatment can be 
identified and change in body mass index (BMI) can be assessed. A study by Brixner et 
al. has used GE EMR database to assess the impact of antipsychotics on weight gain.13    
 
Study design 
An ecologic study design was used, which is a type of observational study that 





aggregated data by each calendar quarter can be analyzed for assessing trend of 
overweight and obese for each quarter from 2000 to 2009. Data were aggregated and 
analyzed by calendar quarters to increase the data time points in this study.  A quarter 
was defined as a period of three consecutive calendar months: January 1– March 31; 
April 1– June 30; July1– September 30; and October 1– December 31. 
 
Study population 
Adolescent patients (12–19 years of age) with a documented physician office visit 
within the GE EMR database, denoted as activity, were eligible for inclusion in this 
study. The exposed group was comprised of adolescents with at least one prescription for 
any SGA or first generation antipsychotic (FGA) between the years January 2000 and 
July 2009. Even though the data was available until July 2010 the recruitment period 
ranged from January 2000 to July 2010 to allow 1 year follow-up period for patients with 
prescription in July 2009. Patients were assigned an index date which was their first 
prescription for any SGA or FGA in the GE EMR database. Subsequent prescriptions for 
any FGA or SGA after the index prescription were also identified. Only those 
prescriptions with documented activity at least 365 days post prescription date were 
retained so that each prescription had at least 365 days of follow up period available in 
the GE EMR database. Although a follow-up period of 365 days was chosen arbitrarily, it 
is a common practice to use 365 days follow-up period in retrospective observational 
studies. The index prescription and subsequent prescriptions were categorized to first, 
second, third, or fourth quarter of each year within the years 2000–2009 based on the 





first prescription per patient per quarter was included in this study and any subsequent 
prescriptions within the same quarter were excluded. This was done to ensure that each 
patient contributed only one observation per quarter and to prevent duplication of 
prevalence estimates within each quarter. Each patient was then followed for a period of 
1 year from the date of prescription and all available BMI values 1 month after the 
prescription date within this time period were obtained. Only those patients with at least 
12 months of documented activity from date of prescription and at least one BMI value 1 
month after the prescription date within the follow up period were eligible for inclusion 
in this study. This was done to allow at least 1 month for change in BMI after 
antipsychotic prescription.  
The comparison population was identified based on presence of an activity 
(medical visit or prescription) in the GE EMR database and no prescriptions for any 
antipsychotic medications. After identifying the comparison population, we used 
stratified random sampling from the population with 3:1 matching on age, gender, and 
calendar quarter of antipsychotic prescription in the database to identify the comparison 
group.   
Excess weight for children and adolescents is defined based on the year 2000 
CDC gender-specific BMI-for-age growth charts.15 Children and adolescents with BMI 
between the 85th and 95th percentile are considered overweight and those at and beyond 
the 95th percentile are considered obese.16 For patients with more than one BMI value in a 
year, the maximum value was selected for analysis. Gender-specific CDC growth charts 
were used to identify patients with follow-up BMI at or above the 85th or 95th percentile 





of exposure and comparison group patients with BMI at or above the 85th or 95th 
percentile by quarter.  
Baseline medical conditions such as dyslipidemia, hypertension, obesity, 
hypothyroidism, schizophrenia, bipolar disorder, depression, type 2 diabetes, and mental 
illness may influence weight. This study was approved by the institutional review board 




Quarterly means and proportions for demographic characteristics such as age, 
race, geographic region, and insurance type were calculated and averaged for the study 
period. Similarly, mean proportion of concomitant medication use and baseline medical 
conditions was also evaluated for each quarter and averaged for the study period. 
Quarterly means were averaged for all quarters from January 2000–July 2009 to provide 
an estimate of distribution throughout the study period for exposed and unexposed 
groups. T tests with unequal variances were used to illustrate differences, if any, in the 
average demographic, concomitant medication use, and baseline medical conditions 
between the exposure and comparison group for the whole study period. The trend of 
age-and gender-stratified prevalence of subjects with BMI ≥85th and ≥95h percentile was 
plotted for each quarter from 2000 to 2009 for the exposed and comparison groups. 
Lowess smoothing technique was used to smooth the trend of prevalence of BMI ≥85th 
and ≥95th percentile for exposed and comparison group for graphical comparisons.17 
Prevalence of subjects with BMI ≥85thand ≥95h percentile for the exposed and 





year 2008–2009. Seemingly unrelated estimation test in STATA was used to compare the 
slope coefficients of age stratified prevalence of BMI ≥85thand ≥95th percentile separately 
for the exposed and comparison groups.18   
 All analyses were performed using SAS Version 9.2 (SAS Institute, Cary, NC) 
and STATA Version 10.0 (StataCorp. 2007. Stata Statistical Software: Release 10. 





The GE EMR database consisted of approximately 1.8 million patients 0-19 years 
old. Of these, 24,109 patients had at least one prescription for FGAs or SGAs and 
approximately 1.7 million had at least one documented activity in the GE database 
without a single prescription for antipsychotic agent.  Of these, only 9,374 exposure 
group adolescents and 669,207 comparison group adolescents had at least one 
documented activity 12 months post index date. A total of 6,183 and 387,435 patients in 
the exposure and comparison group, respectively, had at least one follow-up BMI 1 
month post index date/activity and were eligible for inclusion in this study (Figure 2). 
The exposed group (n=6,183) had multiple prescriptions for antipsychotic agents 
longitudinally in the GE EMR database with  8,128 observations contributed by males 
and 5,425 observations contributed by females assigned to respective quarters based on 
the date of prescription. The final comparison group consisted of a stratified random 
sample matched to the exposed group by distribution of gender, age, and calendar quarter 





Table 2 presents the mean demographic and baseline medical conditions in the 
exposed and unexposed groups. The mean age was similar between the exposure and 
comparison group males and females respectively. The mean proportion of exposed 
males and females from the Midwest region was highest (41.16% and 37.01%) compared 
to the comparison group males (16.33% and 16.87%) respectively. The comparison group 
males and females had significantly higher proportion with commercial insurance 
(p<0.01). However, the exposure group males and females had significantly higher 
proportion with Medicaid insurance (p<0.01). 
The mean BMI during the study period for both the exposed group males and 
females (Table 2) was significantly higher compared to the mean BMI of the comparison 
group males and females, respectively (p<0.001). The mean percentage of males with 
BMI ≥ 85th and 95th percentile (58.09% and 38.83%) from the exposure group was higher 
than the comparison group (46.49% and 26.57%) for the entire study period. The mean 
percentage of females with BMI ≥ 85th and 95th percentile (57.61% and 34.54%,) was 
slightly lower than males. However it was significantly higher compared to the female 
comparison group (42.62% and 20.81%). Both exposure group males and females had 
higher anticonvulsant use (18.93%). However, only the comparison group males had 
higher corticosteroid use (7.89%). Both exposure group males and females had a similar 
percentage of subjects with mental illness (37.29% and 37.16%), respectively which was 
significantly higher compared to the comparison group (13.73% and 13.61%). There 
were significant differences among other baseline medical conditions but the mean 





The annual prevalence of BMI ≥85th (Figure 3) and ≥95th (Figure 4) percentiles in 
exposure and comparison group by gender were plotted for visual inspection and analysis 
of linear trend over time. Table 4 presents the trend analysis of BMI ≥ 85th and 95th 
percentile among exposure and comparison group adolescents by gender from 2000 to 
2009. The proportion of males with BMI ≥85th  and ≥95th percentile for the exposed 
group significantly decreased by 0.25% and 0.31%, respectively, for each quarter from 
2000 to 2009 (p<0.05). On the contrary, the proportion of males with BMI ≥85th 
percentile for the comparison group increased by 0.09% for each quarter from 2000 to 
2009 (p<0.05).  The linear trends of BMI ≥85th and ≥95th percentile among the exposed 
and comparison group males were significantly different from each other (p=0.001 and 
p=0.003, respectively).  
Among exposed females, significant increase of 0.35% was observed in the 
prevalence of BMI ≥95th percentile (p=0.011). The comparison group females did not 
show significant change in prevalence of BMI ≥85th and ≥95th percentile from 2000 to 
2009. The linear trend of BMI ≥95th percentile among the exposed and comparison group 
females were significantly different from each other (p=0.011, respectively).   
Prevalence estimates among adolescent male and female exposure and 
comparison group in 2008–2009 are shown in Table 3. The prevalence of overweight 
BMI was higher for exposure group females compared to the exposure group males. On 
the contrary, the prevalence estimates for obese comparison group males was higher than 
for females. Also, the magnitude of difference between the exposure and comparison 






Overall, the prevalence of overweight and obese from 2000 to 2009 was found to 
be higher among male and female antipsychotic users compared to the male and female 
comparison group, respectively. However, the trend of overweight and obese adolescent 
male antipsychotic users was decreased while the trend of overweight and obese 
nonantipsychotic user males increased from 2000 to 2009. The decreasing trend in male 
antipsychotic users may be associated with better management of excessive weight gain 
or use of antipsychotics with lower potential for weight gain. Contrary to males, the trend 
in the prevalence of overweight and obese in female antipsychotic users increased while 
the trends for nonantipsychotic user females remained unchanged from 2000 to 2009. 
The increasing trend of prevalence of obesity observed in adolescent female 
antipsychotic users may be associated with the increased likelihood of excessive weight 
gain in females compared to males.19-22 A study conducted by McIntyre et al. reported 
that girls 13 years or older exposed to antipsychotics had higher odds of 
obesity/excessive weight gain compared to boys.22  Studies have shown that 
antipsychotics induce hyperprolactinemia in women which promotes appetite and insulin 
resistance.23, 24 Increased prolactin levels may be associated with the increased likelihood 
of excessive weight gain among females. 
 The trend of prevalence of overweight and obesity among female comparison 
group remained stable and did not show statistically significant change. There may not be 
a significant difference in prevalence of overweight and obesity between each quarter to 
see a statistically significant difference in trend.  Although not significant, the negative 





above the 85th and 95th, percentile among adolescent females is decreasing over time. A 
decrease in prevalence of overweight and obese among nonusing females can be 
corroborated by the fact that the adolescent females had the lowest prevalence estimates 
for overweight and obesity in 2008–2009 compared to males. Societal pressure and peer 
pressure of being normal weight and the stigma attached with being overweight among 
adolescent females could be the reason for lower prevalence of high BMI in this age 
group.25, 26 
In this study the proportion of males was higher than for females and the mean 
age of females was higher than the mean age of males. This is consistent with other 
studies where males were more likely to be prescribed an antipsychotic agent compared 
to females27, 28 and female antipsychotic users tended to be older than males.28 Males may 
be more likely to be prescribed antipsychotics compared to females because of the higher 
likelihood of excessive weight gain among females associated with antipsychotic use.  
   This study has several strengths. This study is the first to compare the 
prevalence of overweight and obesity in adolescent antipsychotic and nonantipsychotic 
users using a large national electronic medical record database over a long period of time 
(10 years). Another strength of this study is the use of a stratified random comparison 
group. Stratified random sampling ensured that the age and gender distribution was 
sufficiently represented in the comparison group. BMI is age and gender dependent. 
Therefore matching was performed based on age and gender in this study. Proper 
distribution of BMI and age allows appropriate comparison between exposure and 
random comparison group. Stratified random sampling also controlled for any seasonal 





The results of this study should be viewed in light of several limitations. This 
study used an ecologic study design. Therefore the potential for ecologic fallacy cannot 
be rejected. One of the most important limitations of the study is that prescriptions in an 
EMR database are tracked by prescription orders and medication lists and not by actual 
prescriptions filled at the pharmacy. We cannot be entirely sure if patients are filling the 
medications prescribed to them. Also, patients with at least one prescription order for 
antipsychotic drug were considered to be on the drug during the follow-up period.  This 
may have resulted in misclassifying patients as antipsychotic user even if the patients 
were not actively or regularly taking the drug during the follow-up period. The results 
(proportion of overweight) may be biased towards the null because misclassified 
antipsychotic users who are not regularly taking antipsychotics may have very little 
impact on their weight. Another limitation of the database is that it is predominantly 
primary care physician network database and, therefore, health care received outside of 
the primary care setting may not be captured in the database. This dataset likely includes 
antipsychotic users who are relatively less severe as compared to those patients seeking 
care from psychiatrists or other mental health specialists. As a result the results may be 
biased towards the null since we are automatically excluding sicker or more severe 
patients.  
The prevalence estimates of overweight and obesity for nonantipsychotic users 
provided in this study may be higher than the general population. A recent study by 
Ogden et al. estimated the prevalence of high BMI in US children and adolescents using 
the National Health and Nutrition Examination Survey (NHANES) database.29 The 





NHANES were lower compared to 2008-2009 prevalence estimates for current study 
(34.2% vs. 45.9% and 18.1% vs.25.24% for ≥85th and ≥95th percentile respectively). The 
GE EMR database used in the current study consists of patients with predominantly 
primary care visits and the comparison group included patients not on antipsychotics but 
with other medical conditions. This may have resulted in a selection bias and the patients 
in the comparison group may be sicker than individuals participating in the NHANES 
study and may not be appropriate controls. On the other hand, the results of the NHANES 





Overall, adolescents on antipsychotics had higher prevalence of overweight than 
nonusing adolescents. The trend of prevalence of overweight and obese among male 
antipsychotic users decreased while the trend of prevalence increased for male nonusing 
adolescents. On the contrary, the trend of prevalence of obesity among female 
antipsychotic users increased while the prevalence remained stable among female 
nonusing adolescents. Antipsychotic treatment may have differential impact on weight 
gain in adolescent males and females or a disparity in monitoring metabolic parameters 
may exist between adolescent males and females. More research is needed that assesses 
the weight gain potential of antipsychotic treatment among adolescent males and females 
separately. Also, future studies should assess the monitoring patterns of metabolic 
parameters in adolescents treated with antipsychotics to assess if any disparity exists in 






Table 2 Mean Demographic and Baseline Conditions in Exposure and Stratified Random 














% % P 
value % % 
P 
value 
Age (Mean, SD) 14.86 (0.28) 14.86 (0.28) 1.000 15.98 (0.34) 15.98 (0.34) 1.000 
Region       
Northeast 25.05 27.74 0.173 31.18 31.07 0.965 
Midwest 41.16 16.33 0.000 37.01 16.87 0.000 
South 23.87 37.77 0.000 21.33 34.05 0.000 
West 9.94 18.17 0.000 10.48 18.04 0.000 
Insurance Type      
Commercial 35.73 46.62 0.000 40.77 47.54 0.001 
Medicare 4.28 0.37 0.000 2.62 0.13 0.000 
Medicaid 24.14 3.84 0.000 17.77 4.81 0.000 
Self-pay 3.76 2.49 0.239 3.06 3.14 0.884 
Other/Unknown 3.76 2.49 0.374 3.06 3.14 0.884 
BMI       
Avg. Quarterly 
BMI 
25.99 24.43 0.000 27.48 25.14 0.000 
BMI ≥85th 
percentile 
58.09 46.49 0.000 57.61 42.62 0.000 
BMI ≥95th 
percentile 
38.83 26.57 0.000 34.54 20.81 0.000 
       
Medications       
Beta Blockers 2.04 0.64 0.000 3.35 0.99 0.000 
OAB Wt. Gain 0.89 2.76 0.000 0.57 2.74 0.000 
OAB Wt. Loss 0.68 0.61 0.582 0.88 1.31 0.052 
Antidepressants 3.24 1.04 0.001 4.26 1.57 0.000 
Anticonvulsants 18.93 1.26 0.000 14.28 1.24 0.000 
Corticosteroids 5.47 7.89 0.001 6.40 6.36 0.955 
Anorexiants 0.12 0.02 0.008 0.15 0.18 0.537 
Antiobesity 0.10 0.09 0.888 0.32 0.23 0.518 
Oral Contraceptive 0 0  4.84 4.07 0.268 
Baseline Conditions      
Dyslipidemia 0.67 0.23 0.004 0.29 0.19 0.240 
Hypertension 0.89 0.54 0.090 0.68 0.35 0.021 
Obesity 2.81 2.39 0.222 3.66 2.67 0.010 
Hypothyroidism 0.73 0.25 0.005 1.31 0.57 0.002 
Schizophrenia 1.13 0.00 0.000 0.92 0.00 0.000 
Bipolar Disorder 6.75 0.27 0.000 8.14 0.29 0.000 
Depression 2.15 0.71 0.002 3.15 1.05 0.000 
Type 2 Diabetes 3.91 1.12 0.000 5.10 1.89 0.000 
Mental Ilness^ 37.29 13.73 0.000 37.16 13.61 0.000 







Table 3 Prevalence of Overweight and Obese in Exposure Group and Comparison Group 







  12-19 y 12-19 y 12-19 y 
BMI  ≥95th 
percentile 
   
Both Sexes 35.45% 25.24% 10.21% 
Males 34.70% 27.62% 7.07% 




   
Both Sexes 56.32% 45.95% 10.37% 
Males 54.91% 47.59% 7.31% 







Table 4 Trend Analysis of BMI ≥85th and ≥95th Percentile Among Exposure Group and 
Comparison Group Adolescents by Gender, 2000-2009 
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 Figure 2 Flowchart of Patient Selection 
Patients 0-19 years in the GE EMR dataset from January 2000 to July 2010 
N=1.8 Million  
 
Patients with at least one 
prescription for FGAs or SGAs 
N=24,109 
Patients with at least one 
follow up BMI one month post 
index date during 12 month 
follow up period 
N=6,183 
Patients with a follow up BMI 
one month post index activity 
date during 12 month follow up 
period 
N=387,435 
 Patients with at least one 
activity in the GE EMR 
 N=1,787,850 
Patients 12-19 years with at 
least one documented activity 
12 months post index date  
N=9,374 
Patients 12-19 years with at 
least one documented activity 
12 months post index activity 
N=669,207 



















Stratified Random Sampling 





   
 
Figure 3 Percent of BMI ≥ 85th Percentile in Exposure and Comparison Group Males and Females Aged 12 Through 19 Years 













































   
 
Figure 4 Percent of BMI ≥ 95th Percentile in Exposure and Comparison Group Males and Females Aged 12 Through 19 Years 
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Objective: To assess the frequency and predictors of regular monitoring of metabolic 
parameters as recommended by the American Diabetes Association (ADA)/ American 
Psychiatric Association (APA) guidelines in adolescents (12–19 years old) receiving 
antipsychotic prescriptions compared to an age and gender matched comparison group. 
Methods: A retrospective cohort study was conducted using an ambulatory care 
electronic medical record database in the United States from January 2004 to July 2009. 
The exposure group consisted of adolescents with first prescription for SGAs (denoted as 
index date). The comparison group, selected from those without antipsychotics, was 
matched (3:1) to the antipsychotic medication group on age, gender, and month of index 
antipsychotic prescription. Baseline and follow-up metabolic measurements were 
assessed and patients were categorized as being regularly monitored if the frequency of 
measurements were as recommended by the ADA/ APA guidelines over the 395 day 
follow up. Multivariate logistic regression was conducted to assess the predictors of 
regular monitoring, adjusting for demographic characteristics, baseline medications, and 
baseline medical conditions. Results: The exposure and comparison group consisted of 
3,038 and 9,114 subjects, respectively, (mean age 15.53 years, 54% males). The 
frequency of monitoring of BMI, lipids, total cholesterol, and fasting blood glucose as 
recommended by ADA/APA guidelines among antipsychotic users (25%, 55%, 1.7%, 
and 2%) was low but significantly higher compared to the matched comparison group 
(9.5%, 37.4%, 0.8%, and 0.8%, respectively) (p<0.05). Overall, antipsychotic treatment 
was associated with 1.5 to 4.26 fold increase in likelihood of metabolic monitoring 





antidiabetic use for BMI monitoring (Odds Ratio [OR], 3.65; 95% confidence interval 
[CI], 2.19–6.08); high blood cholesterol levels for blood pressure (OR, 3.17; 95% CI, 
2.02–4.08), total cholesterol (OR, 11.85; 95% CI 6.09–23.05), and fasting blood glucose 
(OR, 7.81; 95% CI, 3.62–16.86).  Conclusion: We observed that the majority of 
adolescents on antipsychotics are under monitored for BMI, lipids and glucose levels. 
Antipsychotic users with preexisting and newly diagnosed metabolic conditions were 
more likely to be regularly monitored for metabolic parameters than antipsychotic users 
without such conditions. Without regular monitoring of metabolic parameters, 
adolescents on antipsychotics may grow into adulthood with abnormal weight and other 






Second generation antipsychotics (SGAs) are used as first line treatment for 
schizophrenia, 1 bipolar disorder, 2 and major depressive disorder.3 The national trend of 
prescriptions for antipsychotics in adolescents has sharply increased in the United States. 
The annual number of visits that included antipsychotic prescription increased from 274.7 
in 1993 to 1,438.4 in 2002 per 100,000 population younger than 21 years. 4 The 
American Diabetes Association (ADA)/ American Psychiatric Association (APA) 
guidelines, published in February 2004, recommend monitoring of metabolic parameters 
such as weight and body mass index (BMI), blood pressure, fasting plasma glucose, and 
fasting lipid profile for all patients receiving antipsychotic treatment regardless of age.5 





drawn from the areas of psychiatry, obesity, and diabetes including representatives from 
the United States Food and Drug Administration (FDA) and the pharmaceutical industry.5  
In 2004, the FDA required all manufacturers of SGAs (atypical antipsychotics), such as 
Clozaril ® (clozapine), Risperdal ® (risperidone), Zyprexa ® (olanzapine), Seroquel ® 
(quetiapine), Geodon ® (ziprasidone), and Abilify ® (aripiprazole), to add a new warning 
to the drugs’ labels about the increased risk of hyperglycemia and diabetes.6 In 2010, the 
FDA changed prescribing information for olanzapine, with recommendations that 
physicians consider the increased potential for weight gain, hyperlipidemia, and long-
term risks in adolescents using the medication.7  
Previous studies have assessed the monitoring patterns of metabolic parameters 
among adults on antipsychotics which have been relatively low in commercially insured 
populations.8, 9 A study conducted by Haupt et al. in commercially insured adults found 
that 9% and 17% received lipid and glucose testing within 12 weeks of starting SGA 
medication. Another study by Morrato et al. conducted using administrative data from 2 
managed care plans reported that only 13% of adults had glucose and lipid testing within 
6 months of starting antipsychotic medication.9 The findings from a study conducted in 
veterans reported relatively better monitoring rates of 39% for lipids and 57% for glucose 
testing, respectively, within 6 months of initiating SGA therapy.10 Only one study 
assessed the monitoring of metabolic parameters using Medicaid data specifically among 
adolescents. The authors reported that lipid and glucose testing was performed in 13% 
and 32% of children and adolescents occurring 30 days before through 180 days after 





national population as the Medicaid population is usually sicker than the commercially 
insured population.11  
Very little information exists in the literature regarding the monitoring of 
metabolic parameters in the national population with commercial insurance treated in a 
primary care setting  Most importantly, none of the studies to date have assessed the 
monitoring of body mass index (BMI) and blood pressure in adolescents on 
antipsychotics. The ADA/APA guidelines suggest that physicians need to do a careful 
review of baseline metabolic parameters before or as soon as initiating antipsychotic 
treatment.5 None of the studies conducted in adolescents have assessed the monitoring of 
metabolic parameters prior to initiating antipsychotic treatment (baseline). Very little 
information exists regarding the predictors of regular monitoring of metabolic parameters 
in adolescents treated with SGAs. A study by Morrato et al. assessed the demographic 
and clinical predictors of monitoring of glucose and lipid testing in SGA treated children. 
The strongest predictors associated with monitoring glucose and lipid testing were having 
an emergency room department visit, multiple mental health comorbidities, office visit, 
and hospitalization.11 The limitation of this study was that it did not include an untreated 
comparison group. Also, the predictors of BMI and blood pressure monitoring were not 
assessed in this study and the question whether antipsychotic use is associated with 
monitoring of metabolic parameters remained unanswered. It remains unknown whether 
demographic characteristics, insurance type, concomitant medication use, and baseline 
medical conditions in addition to antipsychotic use are associated with regular monitoring 





The purpose of the current study was to assess the frequency of regular 
monitoring of metabolic parameters as recommended by ADA/APA guidelines in 
adolescents (12–19 years old) receiving second generation antipsychotics (SGA) 
compared to age and gender matched comparison group in a predominantly primary care 
setting. The rationale for including a healthy cohort in this study was to assess the 
frequency of metabolic monitoring patterns among healthy patients and compare those to 
the monitoring patterns among adolescents on antipsychotics in whom the monitoring is 
recommended. By including a healthy cohort we wanted to assess the incremental impact 
of antipsychotics on monitoring of metabolic parameters.  The secondary purpose of the 
study was to assess if antipsychotic use along with demographic, medications or baseline 







The General Electric (GE) Centricity electronic medical record (EMR) database 
was used for this study. The GE EMR database has data on approximately ten million 
patients. The GE EMR database is comprised of data submitted by more than 70 
consortium member institutions located in more than 40 states. The GE Centricity is an 
EMR system that enables ambulatory care physicians and clinical staff to document 
patient encounters, streamline clinical workflow, and securely exchange clinical data with 
other providers, patients, and information systems. Centricity EMR is used by more than 





widely used ambulatory care EMR. This EMR system replaces the paper medical record 
for the patients in the participating medical offices. The EMR data are submitted 
voluntarily from physician groups across the country.  A variety of practice types are 
represented ranging from solo practitioners to community clinics, to academic medical 
centers and large integrated delivery networks. The resulting research database provides 
information reflective of the clinical data captured in the practice setting, including 
diagnoses, chief complaints, medication orders, medication lists (patient-reported 
prescription and over-the-counter drug use), laboratory orders and results, and biometric 
readings. Data are collected centrally and go through a quality control process to clean 
the data and remove invalid values. The EMR database is deidentified and HIPAA 
compliant. Previous studies have used the GE EMR database in health outcomes 





A retrospective cohort study design was used for this study. The retrospective 
cohort consisted of adolescents 12-19 years old. Within this cohort, adolescents with 
prescription for antipsychotics were considered the exposed group. The monitoring of 
this group was compared to what the guidelines recommend controlling for sporadic 











Patients were eligible for inclusion in the exposure group if they 1) were 12–19 
years old and, 2) had at least one prescription (index activity) for any SGA between 
January 2004 and July 2009 and, 3) had at least one documented physician visit ≥180 
days before the index date and at least one documented physician visit 395 days after the 
index date and, 4) had no prescription for any antipsychotic agent during the 180 days 
before the index date (Figure 5). The comparison group in this study was selected from 
those without any antipsychotic medications. Patients in the comparison group were 
eligible for inclusion in this study if they 1) were 12–19 years old and, 2) had no 
prescription for any antipsychotic agent between January 2004 and July 2009 and, 3) had 
at least one documented physician visit ≥180 days before the index date and at least one 
documented physician visit 395 days after the index date. This was done to ensure that 
each patient had EMR data for at least 570 days (19 months) and to make sure that we 
were including patients who have healthcare coverage and are regularly visiting the 
physician during that time period. This methodology has been applied in previous 
publications based on the GE database.12-14  
The date of patients’ first prescription for any SGA after a pre index period of 180 
days in the GE EMR database was selected as the index date for the exposed group. The 
antipsychotic drug prescribed on the index date was designated as the index drug. 
Patients were categorized as exposed to individual SGAs by their index drug. The follow-
up period was 395 days from the index date.  
Among the exposed individuals, analysis was limited to patients who remained on 





Stratified random sampling with 3:1 matching was used and the comparison group was 
matched to the exposed based on age, gender, and month of visit to the index 
antipsychotic prescription date. 
Figure 6 provides the schematic of the study design. Electronic medical records 
for eligible patients were examined for presence of baseline and follow-up metabolic 
measurements such as BMI, blood pressure, total cholesterol, and fasting blood glucose 
levels. Metabolic measurements that occurred within 15 days before or after the index 
date were classified as baseline measurements. Fifteen days pre and postindex date was 
selected to allow one month for assessing baseline metabolic measurements. The 
guidelines mention that baseline measurements need to be assessed before initiating 
antipsychotic treatment or as soon as after initiating treatment. Therefore we used 15 days 
pre and post index date as a reasonable window for assessing baseline metabolic 
measurements. Metabolic measurements occurring within 16th day after the index date 
through the end of follow-up (index date + 395 days) were classified as follow-up 
measurements. A follow-up period of 395 days was used instead of 365 days to account 
for any gaps in therapy and to allow at least 30 days of follow-up period for antipsychotic 
prescriptions prescribed closest to the 365th day. 
Demographic characteristics including age, gender, insurance type, and region 
were assessed during the 180 days preindex period. Insurance type and region were 
assessed to illustrate the baseline differences by insurance type and regional variation. 
Baseline medication use of beta blockers, oral antidiabetic agents associated with weight 
gain (such as human insulin, sulphonylureas, and thiazolidinediones) or loss (such as 





corticosteroids that may influence metabolic monitoring was assessed during the 180 
days preindex period. Baseline medical conditions such as dyslipidemia, hypertension, 
obesity, hypothyroidism, type 2 diabetes,  bipolar disorder, schizophrenia, depression, 
and other mental illness that may influence metabolic monitoring were identified, using 
ICD-9 codes, in both the 180 days preindex and 395 days follow-up period. Newly 
diagnosed baseline medical conditions were defined as those conditions that were newly 
identified during the follow-up period for which there was no evidence in the preindex 
period. 
The ADA/APA monitoring guidelines were used as a reference standard to 
categorize patients as being monitored regularly or irregularly for metabolic parameters.15 
According to the guidelines, BMI should be monitored at least 6 times during the one 
year follow-up period in addition to the baseline measurement. Fasting glucose and blood 
pressure should be monitored at least 2 times in the follow-up period in addition to 
having at least one baseline measurement. Lipid levels should be monitored at least 1 
time in addition to having baseline measurement.. Based on these criteria, patients in the 
exposure and comparison group were categorized as being regularly monitored if the 
number of measurements was ≥7 for BMI, ≥3 for blood pressure, ≥2 for total cholesterol, 





Tests of proportions were used to evaluate differences between the antipsychotic 
group and comparison group in baseline demographics, baseline medications, baseline 





parameters. Wilcoxon rank sum test was used to compare the mean number of metabolic 
measurements between the antipsychotic group and comparison group. Separate 
multivariate logistic regression analyses were conducted to assess the likelihood of 
regular monitoring of BMI and blood pressure. The frequency of monitoring of lipids and 
fasting blood glucose was extremely low, since they are done less frequently than blood 
pressure or BMI, for logistic regression modeling. To account for rare events, separate 
multivariate logistic regression for rare events was conducted to assess the likelihood of 
regular monitoring of total cholesterol and fasting blood glucose.16, 17 The logistic 
regression for rare events uses methods with a lower mean square error thereby 
increasing the probability of an event. The regression analyses were conducted 
controlling for the individual SGAs, presence of baseline metabolic measurements, 
demographic characteristics, baseline medications, and baseline and newly diagnosed 
baseline medical conditions thought to be related to monitoring of metabolic parameters. 
All analyses were performed using STATA Version 10.0 (StataCorp. 2007. Stata 
Statistical Software: Release 10. College Station, TX: StataCorp LP). This study was 
approved by the institutional review board at the University of Utah on September 24th 





 A total of 7,967 patients 12–19 years old with at least one prescription for a single 
type of SGAs were identified in the GE EMR database between the January 2004 and 
July 2009. Of these, the final sample consisted of 3,038 patients with at least one 





physician visit 395 days after the index date. The comparison group consisted of 9,114 
patients randomly matched to the exposure group. See Figure 5 for details of patient 
selection. 
Table 5 provides the comparison of demographics, baseline medication use, and 
baseline medical conditions among patients in the exposure group and the matched 
comparison group. The mean age (15.53 years; SD, 2.22) and gender distribution (54% 
males) of patients in the exposure and comparison group was similar (p>0.05) as 
expected since matching was based on age and gender.  A significantly higher percentage 
of exposed were from the South and Northeast US region while significantly higher 
percentage of the comparison group were from Midwest and West (p<0.01). The 
proportion of exposed with Medicare insurance was significantly higher than the 
comparison group (p<0.01).  Patients in the exposure group had higher percentage of 
concurrent prescriptions for beta blockers, oral antidiabetic medications associated with 
weight loss, antidepressants, and anticonvulsants (p<0.01) while the comparison group 
had higher proportion on oral antidiabetic medications associated with weight gain, and 
corticosteroids (p<0.01) during the study period. The exposed had significantly higher 
proportion of baseline conditions including obesity, type 2 diabetes, and psychiatric 
conditions such as bipolar disorder, schizophrenia, depression, and other mental illness 













Frequency of baseline monitoring in the exposed  
and comparison group 
Table 6 presents the frequency of baseline monitoring of metabolic parameters 
among adolescents on individual antipsychotics and the comparison group. If the 
guidelines were fully implemented, 100% of exposed patients would have baseline 
measures for each of the four metabolic parameters, but 0.63% of exposed patients had 
complete baseline monitoring.  Patients on quetiapine had higher rates of baseline 
monitoring of BMI (51.7%), blood pressure (72.7%), total cholesterol (3.21%), and 
fasting blood glucose (4.59%) compared to the frequency of baseline monitoring of BMI 
(44.4%), blood pressure (62.6%), total cholesterol (1.8%), and fasting blood glucose 
(3.2%) in the comparison group. Patients on risperidone and olanzapine had higher rates 
of baseline monitoring of BMI (52.4% and 55.0%), blood pressure (58% and 74.4%), and 
fasting blood glucose (5.26% and 3.9%), respectively, compared to the comparison 
group. Patients on aripiprazole had higher baseline monitoring for BMI (52.2%) and total 
cholesterol (5.0%, p<0.01); and ziprasidone had higher frequency of monitoring for total 




 Metabolic measurements in the exposed and comparison group 
 Table 7 presents the mean number of metabolic measurements among adolescents 
on individual antipsychotics and the comparison group during the one year follow-up 
period relative to the ADA/APA guideline recommendations. Adolescents on individual 
antipsychotics had lower mean number of metabolic measurement relative to those 





Adolescents on individual antipsychotics had significantly higher mean number of BMI, 
blood pressure, total cholesterol, and fasting blood glucose measurements compared to 
the group not prescribed SGAs (p<0.01).  
 
Frequency of regular monitoring among the exposed and  
comparison group  
There was evidence of adherence to monitoring for all metabolic parameters in 
the EMR for <1% of patients on antipsychotics. Regular monitoring of all four metabolic 
parameters as recommended by the ADA/APA guidelines was extremely low and not 
significantly different between the exposed and healthy comparison groups (p>0.05), 
except for patients on aripiprazole where the frequency was slightly higher (p<0.01).  
Table 8 presents the frequency of regular monitoring of metabolic parameters in 
adolescents on antipsychotics and the comparison group from 2004 to 2009. The 
frequency of regular monitoring of BMI and blood pressure was significantly higher 
among patients on individual antipsychotic agents such as aripiprazole (26.2% and 
52.8%), olanzapine (23.3% and 62.2%), risperidone (24.9% and 49.0%), quetiapine 
(25.0% and 59.5%), and ziprasidone (29.2% and 54.9%) compared to the comparison 
group (9.5% and 37.4%, p<0.01), respectively. Similarly, the frequency of regular 
monitoring of total cholesterol (3.6%, 1.9%, 2.1%, 6.2%) and fasting blood glucose 
(1.6%, 1.4%, 1.7%, 4.4%) was significantly higher among adolescents on aripiprazole, 
risperidone, quetiapine, and ziprasidone respectively compared to the frequency of 
regular monitoring of total cholesterol (0.8%) and fasting blood (0.7%) in the comparison 





of total cholesterol (p=0.478) but significantly higher frequency of regular monitoring of 




Predictors of BMI and blood pressure monitoring 
 Table 9 presents the predictors of regular monitoring of BMI and blood pressure. 
Antipsychotic treatment was a significant predictor of regular monitoring of BMI and 
blood pressure among adolescents. Patients on risperidone had the highest odds ratio of 
2.65 followed by ziprasidone (OR: 2.62; 95% Confidence Interval [CI], 1.68–4.09), 
olanzapine (OR, 2.60; 95% CI, 1.89–3.57), aripiprazole (OR, 2.46; 95% CI, 1.89–3.57), 
and quetiapine (OR, 2.35; 95% CI, 1.98–2.80) for regular monitoring of BMI compared 
to the comparison group. Similar to BMI monitoring, being on antipsychotic treatment 
was significantly associated with higher likelihood of regular monitoring of blood 
pressure except for ziprasidone. Although statistically significant odds ratios were 
observed for regular monitoring of blood pressure, the likelihood of regular monitoring 
between the antipsychotic agents was not significantly different from each other because 
the confidence intervals for individual antipsychotics overlapped with each other. 
Compared to males, females were 1.52 and 1.44 times more likely to be regularly 
monitored for BMI and blood pressure, respectively. Patients on medications such as oral 
antidiabetic agents, corticosteroids, or with baseline medical conditions such as obesity, 
type 2 diabetes, and other mental illness were more likely to be regularly monitored for 
BMI and blood pressure. Given usual clinical practice, one might assume that adolescents 
are monitored for BMI and blood pressure at every physician office visit. According to 





with dyslipidemia were highly likely to be regularly monitored for blood pressure but this 
condition was not a significant predictor of monitoring BMI. Newly diagnosed baseline 
medical conditions such as dyslipidemia and type 2 diabetes significantly increased 
monitoring of BMI and blood pressure during the follow-up period. The proportion of 
case patients experiencing regular monitoring of BMI and blood pressure increased by 
24% and 11% each year from 2004 to 2009, respectively, indicating an increase in the 




Predictors of lipid and glucose monitoring 
Antipsychotic treatment was significantly associated with regular monitoring of 
total cholesterol and fasting blood glucose among adolescents. The likelihood of being 
regularly monitored for total cholesterol ranged from 2.48 (95% CI, 1.45–4.26) for 
risperidone, 2.52 (95% CI, 1.50–4.25) for quetiapine, 4.21 (95% CI, 2.50–7.08) for 
aripiprazole, and 7.34 (95% CI, 3.11–17.34) for ziprasidone compared to the comparison 
group. Statistically significant differences in odds were not observed for patients on 
olanzapine for regular monitoring of lipids but patients on olanzapine were 3 times more 
likely to be regularly monitored for fasting blood glucose compared to the comparison 
group. Also, patients on ziprasidone were 4 times more likely to be regularly monitored 
for fasting blood glucose. Adolescents on oral antidiabetic agents were associated with 
increased monitoring of total cholesterol and fasting blood glucose. Baseline diagnosis of 
dyslipidemia and newly diagnosed dyslipidemia were associated with increased 
monitoring of both total cholesterol and fasting blood glucose but only adolescents with 





blood glucose. The proportion of case patients experiencing regular monitoring of total 
cholesterol remained unchanged during the study period but regular monitoring of fasting 





The GE EMR database used in this study is a predominantly primary care 
physician network database with a third of data representing care delivered by specialists. 
Therefore any trends observed in this data may be largely representative of primary care 
physicians practice. Primary care physicians are the first line of defense in diagnosing 
and treating psychiatric conditions. Many adolescents receive treatment from primary 
care physicians because of the dearth of child and adolescent psychiatrists. There is 
growing public health concern regarding the metabolic effects of these drugs in the 
adolescent population.18, 19 The ADA/APA guidelines recommend regular monitoring of 
metabolic parameters in adolescents treated with antipsychotics. We assessed the 
frequency of regular monitoring of metabolic parameters as recommended by ADA/APA 
guidelines among adolescents with prescription for SGA compared to an untreated cohort 
in a predominantly primary care setting. Overall, 55% of the adolescents on 
antipsychotics were being regularly monitored for blood pressure, 25% for BMI, and 
approximately 2% for lipids and glucose compared to 9.46%, 7.43%, 0.76%, and 0.71%, 
respectively, in the comparison group as recommended by ADA/APA guidelines in this 
study. The frequency of regular monitoring observed in this study was higher for 
adolescents on antipsychotics than the untreated comparison group. However, the 





was extremely low. Specifically, the monitoring of lipids and glucose was less than 1% 
higher among adolescents with prescription for antipsychotics compared to the untreated 
cohort. Such low numbers are shocking in spite of the FDA requirement of adding 
warning to drug label stating the increased risk of hyperglycemia or diabetes associated 
with antipsychotics. The mean number of metabolic measurements and frequency of 
regular monitoring of metabolic parameters among adolescents on individual 
antipsychotic such as olanzapine, aripiprazole, risperidone, quetiapine, and ziprasidone 
did not appear to vary drastically even though olanzapine is associated with the highest 
risk of diabetes. Most importantly, less than 1% of exposed patients experienced 
monitoring of all four metabolic parameters as suggested by the guidelines which were 
not significantly different from the untreated comparison group. This study has 
demonstrated that relatively fewer numbers of adolescents with prescription for 
antipsychotics were being monitored regularly by clinicians who are treating them. 
Physicians need to be more proactive in monitoring to avoid the risk of development of 
dyslipidemia or diabetes among adolescents on antipsychotics. The reasons for the low 
monitoring of metabolic parameters could not be ascertained in this study and warrants 
further research.  
The frequency of regular monitoring of lipids and glucose was extremely low as 
compared to other published studies. 11, 20 The frequency could be lower because this 
study’s definition of regular monitoring was stringent compared to previous studies. We 
defined regular monitoring of metabolic parameters as recommended by ADA/APA 
guidelines within 1 year of initiating antipsychotic treatment while previous studies 





of antipsychotic prescription including the baseline lipid or glucose measurement. The 
ADA/APA guidelines provide the frequency of monitoring metabolic parameters within 1 
year after the initiation of antipsychotic treatment and the current study was conducted to 
assess the frequency of monitoring of metabolic parameters as recommended by the 
guidelines. Also, previous studies have assessed monitoring patterns among Medicaid fee 
for service clients (6–17 years old) whereas this study assessed the frequency of 
metabolic monitoring in a predominantly primary care setting in a population that may be 
more generalizable as it contained patients with a variety of insurance types (commercial, 
Medicare, and Medicaid enrollees). 11, 20 Overall, the likelihood of monitoring metabolic 
parameters, as recommended by the ADA/APA guidelines published in February 2004, 
increased each year from the year 2004 onwards. Although, the frequency of monitoring 
of metabolic parameters is lower than expected, the results indicate that the guidelines are 
being put into practice gradually. 
Antipsychotic treatment in adolescents was associated with increased monitoring 
of metabolic parameters. However, no differences were observed in the likelihood of 
regular monitoring of metabolic parameters across individual SGAs with the exception of 
fasting blood glucose. Adolescents on olanzapine or ziprasidone were being monitored 
regularly for fasting blood glucose while no differences were observed in the likelihood 
of regular monitoring among other SGAs compared to the comparison group. Even 
though antipsychotic treatment was associated with regular monitoring, the frequency of 
regular monitoring of metabolic parameters as recommended by ADA/APA guidelines 





The strongest predictors of regular monitoring of BMI were oral antidiabetic use 
and new diagnosis of type 2 diabetes. Both of these were stronger predictors of BMI 
monitoring than antipsychotic use.  Adolescents with diagnosis of type 2 diabetes are 
encouraged to lose weight along with healthy eating and regular monitoring of blood 
glucose levels. Also, adolescents with type 2 diabetes may be visiting their primary care 
physician more often than others resulting in an increased monitoring of BMI compared 
to others. Preexisting and new diagnosis of dyslipidemia was found to be the strongest 
predictor of metabolic monitoring of blood pressure, total cholesterol, and fasting blood 
glucose with higher odds ratios than antipsychotic use. This finding is consistent with the 
results of the study by Haupt et al. conducted in adults.8  
Although antipsychotic use was not the strongest predictor of metabolic 
monitoring, adolescents on antipsychotics with preexisting conditions had higher 
likelihood of metabolic monitoring compared to the comparison group with preexisting 
conditions. Adolescents on antipsychotics with preexisting chronic conditions such as 
diabetes and dyslipidemia may be monitored more regularly to manage the inherent 
chronic condition which may worsen because of the increased risk cardiometabolic 
adverse effects linked to antipsychotic treatment. However, the likelihood of regular 
monitoring among adolescents on antipsychotics without preexisting metabolic 
conditions was lower compared to those with preexisting conditions. Baseline diagnosis 
of obesity and mental illness associated with increased metabolic monitoring was 
consistent with previously published studies in children and adults.8, 11, 20  
This study has several strengths. This study is the first to assess the monitoring 





primary care large national electronic medical record database. Previous studies have 
been conducted in Medicaid population. Another strength of this study is that actual 
clinical measures such as BMI values, blood pressure readings, total cholesterol values, 
and fasting blood glucose levels in the GE EMR database were used to assess monitoring 
patterns in children and adolescents on antipsychotics. Previous studies have used current 
procedural terminology (CPT) codes and not actual clinical measures to assess 
monitoring patterns in children and adolescents on antipsychotics. 11, 20 As with any 
research study there are several limitations. One of the most important limitations of this 
study is that prescriptions in an EMR database are tracked by prescription orders and 
medication lists and not by actual prescriptions filled at the pharmacy. We cannot be 
entirely sure if patients are filling the prescriptions or taking prescriptions prescribed to 
them. Due to this limitation, misclassification of exposure may occur. Patients with at 
least one prescription order for an antipsychotic drug were considered to be on the drug 
during the follow-up period.  This may result is misclassifying the patient as an 
antipsychotic user even if the patient is not actively or regularly taking the drug. Due to 
this limitation the results may be biased towards the null and attenuate the effect of 
antipsychotics on metabolic monitoring if one exists. Another limitation of the database 
is that it is predominantly primary care physician network database and, therefore, health 
care received outside of the primary care setting may not be captured in the database. 
This dataset likely includes antipsychotic users who are relatively less severe as 
compared to those patients seeking care from psychiatrists. As a result the results may be 
biased towards the null since we are automatically excluding sicker or more severe 





antipsychotic drugs to children and almost 85% of all prescription for psychotropic 
medications are prescribed by primary care physicians and pediatricians.21  
A significant limitation of the study is the missing BMI, lipids, blood glucose, and 
blood pressure values in the GE EMR database regardless of antipsychotic treatment. The 
foremost reason for missing values may be that the labs were not ordered by the primary 
care physician although results may not have been entered also. Another reason could be 
that the labs were ordered by other clinician than the primary care physician and never 
got entered into the GE database. This limitation may have resulted in a misclassification 
bias which was assumed to have been equally distributed between the antipsychotic 
group and the comparison group. Patients may have been misclassified as irregularly 
monitored when their clinical values were not included in the GE database due to above 
mentioned reasons. The direction of this bias is uncertain because we do not know the 
reason for missing values. The values can be actually missing (not monitored) or just 
missing from the database (in other words the patient is being monitored but values do 
not exist in the database). Future studies should validate the GE EMR data and identify 
the percentage of clinical values that were ordered but not entered in the database. 
Another limitation of this study is the lack of information on socioeconomic status, diet, 
physical activity, or overall health of patients’ parents, which may directly or indirectly 
impact the monitoring of metabolic parameters in patients on antipsychotics in the GE 
EMR data.  
Future studies should survey primary care providers to ascertain the challenges 
associated with monitoring of metabolic parameters among adolescents. Without regular 





growing into adulthood with abnormal weight and other metabolic parameters that impact 
adult obesity and its cardiovascular outcomes.22-25  Strategies to improve awareness of 
ADA/APA guidelines and improve monitoring of metabolic parameters in adolescents on 





Adolescents on antipsychotics are not being monitored according to guidelines 
published by the ADA/APA although their metabolic parameters are being monitored 
modestly more frequently than age and gender matched comparison group. In particular, 
the majority of adolescents treated with antipsychotics remain under monitored for BMI, 
lipids, and glucose as recommended by the ADA/APA guidelines.   Antipsychotic users 
with preexisting and newly diagnosed metabolic conditions were most likely to be 
regularly monitored than antipsychotic users without such conditions. Without regular 
monitoring of metabolic parameters, adolescents on antipsychotics may be more likely to 
grow into adulthood with abnormal weight and other metabolic parameters and impact 
adult obesity and its cardiovascular outcomes. Strategies to increase awareness and 
adherence to ADA/APA guidelines in monitoring metabolic parameters among primary 
care physicians need to be developed. Clinicians need to be more proactive in monitoring 
metabolic parameters among all adolescents receiving antipsychotics prescriptions and 














Subjects 12–19 years in the GE EMR dataset from January 2004 to July 2009 
N=927,186 
Subjects 12–19 years with at least 
one prescription for SGAs  
n=7,967 
Monotherapy subjects with at 
least 180 days of pre index 
activity and at least 395 days of 
post index activity  
n=3,038 
Subjects with least 180 days of 
pre index activity and at least 395 
days of documented activity post 
index 
 n=387,435 
 Subjects with 12–19 years at 
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Table 5 Demographics, Medication Use, and Medical Conditions among Adolescents in 
Exposure and Comparison Group, 2004 to 2009 
  
 
Exposure Group  Comparison Group P 
value n=3,038 n=9,114  
  n % n %  
Age (Mean, SD) 15.53 2.22 15.53 2.22 1.000 
Gender      
Males 1,647 54.21 4,941 54.21 1.000 
Females 1,391 45.79 4,173 45.79 1.000 
Race      
White 1,033 34.00 2,532 27.79 <0.001 
Black 103 3.39 576 6.32 <0.001 
Hispanic 39 1.28 273 3.00 <0.001 
Other 35 1.15 140 1.54 0.124 
Unknown 1,828 60.17 5,591 61.36 0.251 
Region      
Northeast 729 24.00 1,899 20.84 <0.001 
South 1,176 38.71 2,709 29.72 <0.001 
Midwest 542 17.84 2,628 28.83 <0.001 
West 591 19.45 1,878 20.61 0.172 
Insurance Type      
Commercial 1,231 40.52 4,495 49.32 <0.001 
Medicare 565 18.60 686 7.53 <0.001 
Medicaid 48 1.58 19 0.21 <0.001 
Self-pay 65 2.14 215 2.36 0.485  
Other/Unknown 1,129 37.16 3,699 40.59 0.001 
Baseline Medication Use      
Beta Blockers 38 1.25 27 0.3 <0.001 
Antidiabetics Weight Gain 12 0.39 69 0.76 0.034 
Antidiabetics Weight Loss 21 0.69 29 0.32 0.005 
Antidepressants 56 1.84 38 0.42 <0.001 
Anticonvulsants 297 9.78 66 0.72 <0.001 
Corticosteroids 77 2.53 363 3.98 <0.001 
Baseline Conditions      
Dyslipidemia 22 0.72 61 0.67 0.751 
Hypertension 12 0.39 28 0.31 0.465 
Obesity 111 3.65 170 1.87 <0.001 
Hypothyroidism 12 0.39 20 0.22 0.102 
Type 2 Diabetes 130 4.28 71 0.78 <0.001 
Bipolar Disorder 361 11.88 23 0.25 <0.001 
Schizophrenia  25 0.82 2 0.02 <0.001 
Depression  119 3.92 25 0.27 <0.001 
Mental Illness^ 1,168 38.45 669 7.34 <0.001 






Table 6 Frequency of Baseline Monitoring of Metabolic Parameters among Adolescents 
in Exposure and Comparison Group, 2004 to 2009 









    n % n % n % n % 
Comparison 
Group 




3,038 1,582 52.07% 1,988 65.44% 91 3.00% 152 5.00% 
Aripiprazole 
 
642 335 52.18% 387* 60.28% 27 4.21% 32* 4.98% 
Olanzapine 
 
262 144 54.96% 195 74.43% 3* 1.15% 10 3.82% 
Risperidone 
 
931 488 52.42% 540 58.00% 21* 2.26% 49 5.26% 
Quetiapine 
 
1,090 563 51.65% 792 72.66% 35 3.21% 50 4.59% 
Ziprasidone 
 
113 52* 46.02% 74* 65.49% 5 4.42% 11 9.73% 
*p>0.05, test of proportions was used to compare proportion of patients with baseline metabolic parameters 







Table 7 Mean Number of Metabolic Measurements among Adolescents on 
Antipsychotics Compared to Comparison Group Within One Year Relative to ADA/APA 
Recommendations  











≥7 ≥3 ≥2 ≥3 
Comparison 
Group Mean (SD) 
2.53 (3.28) 2.54 (3.28) 0.07 (0.33) 0.14 (0.60) 
Exposure Group 
(All SGAs) Mean 
(SD) 
4.74 (6.28) 3.86 (3.90) 0.17 (0.46) 0.27 (0.75) 
Aripiprazole 
Mean (SD) 
5.12 (6.56) 3.82 (4.13) 0.26 (0.54) 0.28 (0.71) 
Olanzapine 
Mean (SD) 
5.19 (8.25) 4.18 (4.00) 0.11 (0.36) 0.27 (0.74) 
Risperidone 
Mean (SD) 
4.49 (5.52) 3.33 (3.37) 0.16 (0.44) 0.26 (0.83) 
Quetiapine 
Mean (SD) 




4.65 (6.04) 4.17 (4.20) 0.26 (0.60) 0.43 (0.90) 
* Rank sum test was used and P value<0.01 for comparison of number of BMI, blood pressure, total 
cholesterol, and fasting blood glucose measurements among exposure group compared to comparison 







Table 8 Frequency of Regular Monitoring of Metabolic Parameters as Recommended by 
ADA/APA Guidelines among Adolescents in Exposure and Comparison Group, 2004 to 
2009 









    n % n % n % n % 
Comparison 
Group 




3,038 765 25.18% 1,668 54.90% 74 2.44% 53 1.74% 
Aripiprazole 
 
642 168 26.17% 339 52.80% 23 3.58% 10 1.56% 
Olanzapine 
 
262 61 23.28% 163 62.21% 3* 1.15% 6 2.29% 
Risperidone 
 
931 231 24.81% 456 48.98% 18 1.93% 13 1.40% 
Quetiapine 
 
1,090 272 24.95% 648 59.45% 23 2.11% 19 1.74% 
Ziprasidone 
 
113 33 29.20% 62 54.87% 7 6.19% 5 4.42% 
*p>0.05, test of proportions was used to compare proportion of patients with baseline metabolic parameters 





Table 9 Adjusted Odds of Regular Monitoring of BMI, Blood Pressure, Total Cholesterol, and Fasting Blood Glucose among 
Exposed Adolescents Compared to the Comparison Group, 2004 to 2009 
  BMI Blood Pressure Total Cholesterol Fasting Blood Glucose 
  OR 95% CI P OR 95% CI P OR 95% CI P OR 95% CI P 
Age  0.97 0.94 0.99 0.015 1.07 1.05 1.09 0.000 1.04 0.96 1.12 0.305 1.04 0.95 1.15 0.360 
Females (ref=Males) 1.52 1.36 1.70 0.000 1.44 1.33 1.55 0.000 0.63 0.43 0.92 0.016 1.27 0.85 1.89 0.239 
Region  (ref=Northeast)                                 
Southeast 1.47 1.27 1.71 0.000 0.86 0.78 0.96 0.005 0.74 0.48 1.13 0.161 0.95 0.56 1.62 0.855 
Midwest 0.95 0.80 1.12 0.513 0.98 0.88 1.10 0.780 0.65 0.39 1.07 0.090 0.69 0.38 1.25 0.223 
West 0.68 0.57 0.82 0.000 0.89 0.79 1.00 0.042 0.68 0.40 1.16 0.154 1.04 0.61 1.78 0.875 
Insurance Type 
(ref=Commercial) 
        
      
                  
Medicare 1.16 0.98 1.38 0.078 1.06 0.93 1.21 0.386 0.77 0.45 1.32 0.337 0.86 0.41 1.80 0.686 
Medicaid 1.59 0.89 2.85 0.119 1.65 0.97 2.81 0.065 1.71 0.52 5.65 0.381 2.72 0.77 9.63 0.122 
Self-pay 1.19 0.83 1.70 0.349 0.99 0.77 1.28 0.967 0.48 0.07 3.58 0.477 0.60 0.08 4.41 0.615 
Other/Unknown 0.81 0.72 0.92 0.001 0.91 0.84 0.99 0.021 0.77 0.52 1.13 0.181 1.08 0.71 1.64 0.722 
Treatment Group (ref= 
Comparison Group) 
  
                              
Aripiprazole 2.46 2.00 3.04 0.000 1.53 1.28 1.82 0.000 4.21 2.50 7.08 0.000 1.53 0.72 3.24 0.271 
Olanzapine 2.60 1.89 3.57 0.000 2.22 1.70 2.89 0.000 1.65 0.49 5.54 0.420 2.96 1.21 7.25 0.018 
Risperidone 2.65 2.21 3.19 0.000 1.51 1.31 1.76 0.000 2.48 1.45 4.26 0.001 1.82 0.94 3.53 0.077 
Quetiapine 2.35 1.98 2.80 0.000 1.88 1.63 2.16 0.000 2.52 1.50 4.25 0.001 1.78 0.99 3.17 0.052 
Ziprasidone 2.62 1.68 4.09 0.000 1.41 0.95 2.09 0.085 7.34 3.11 17.34 0.000 4.26 1.33 13.65 0.015 
Medications                                 
Beta Blockers 1.55 0.85 2.81 0.149 1.45 0.86 2.43 0.163 3.07 0.87 10.79 0.08 2.18 0.40 11.79 0.365 
OAD Weight Gain 3.65 2.19 6.08 0.000 2.88 1.79 4.63 0.000 3.68 1.00 13.48 0.049 4.44 1.17 16.88 0.029 
OAD Weight Loss 2.99 1.57 5.71 0.001 1.48 0.80 2.74 0.214 4.60 1.17 18.09 0.029 3.72 0.98 14.07 0.053 
Antidepressants 1.57 0.97 2.55 0.068 1.31 0.85 2.01 0.223 1.49 0.34 6.50 0.597 1.64 0.34 7.86 0.539 
Anticonvulsants 1.15 0.87 1.50 0.324 1.10 0.88 1.37 0.424 1.62 0.83 3.15 0.158 1.25 0.55 2.86 0.600 
Corticosteroids 1.40 1.07 1.85 0.016 1.34 1.10 1.64 0.004 1.21 0.48 3.02 0.686 1.35 0.53 3.46 0.533 
Baseline Conditions                                 
Dyslipidemia 1.12 0.60 2.08 0.731 1.60 1.01 2.52 0.044 9.78 4.15 23.03 0.000 7.83 2.95 20.78 0.000 
Hypertension 1.89 0.86 4.14 0.115 1.43 0.72 2.85 0.306         0.65 0.03 15.12 0.787 
Obesity 1.57 1.16 2.12 0.003 1.53 1.19 1.98 0.001 0.61 0.21 1.80 0.373 0.70 0.18 2.76 0.611 
Hypothyroidism 1.38 0.57 3.32 0.471 0.95 0.45 1.97 0.885 1.67 0.27 10.24 0.578 1.72 0.19 15.73 0.630 
Schizophrenia 0.93 0.36 2.41 0.884 0.94 0.43 2.07 0.881                 
Bipolar Disorder 0.98 0.76 1.27 0.896 1.15 0.91 1.44 0.239 1.29 0.64 2.57 0.477 1.13 0.49 2.63 0.774 
Depression 1.00 0.66 1.51 0.997 1.38 0.96 1.97 0.079 0.56 0.13 2.46 0.439 0.68 0.10 4.57 0.693 
Type 2 Diabetes 1.84 1.32 2.55 0.000 1.36 1.00 1.85 0.048 0.90 0.31 2.63 0.852 1.03 0.37 2.86 0.949 
Mental Illness^ 1.52 1.32 1.75 0.000 1.52 1.36 1.70 0.000 0.98 0.64 1.50 0.931 1.42 0.90 2.25 0.133 
Incident Conditions                                 
Dyslipidemia 2.16 1.38 3.39 0.001 3.17 2.02 4.98 0.000 11.85 6.09 23.05 0.000 7.81 3.62 16.86 0.000 
Type 2 Diabetes 2.91 2.09 4.04 0.000 2.75 1.95 3.87 0.000 1.78 0.79 4.01 0.167 4.05 1.92 8.52 0.000 
Year of Index Date 1.24 1.19 1.29 0.000 1.11 1.08 1.14 0.000 1.13 0.99 1.29 0.076 1.31 1.14 1.50 0.000 
OR: Odds Ratio, P: P value, 95% CI: 95% Confidence Interval, ^ Mental Illness was identified using ICD-9 codes 290 to 294 and 297 to 319. The 
logistic regression analysis was adjusted for age, gender, insurance type, individual antipsychotic medications, baseline medications, baseline 
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Objective: To assess the association of second-generation antipsychotics (SGAs) 
prescriptions with changes in weight among adolescents compared to a matched, 
randomly selected age and gender untreated comparison group. Methods: A 
retrospective cohort study was conducted using the General Electric (GE) electronic 
medical record database between January 2004 and July 2009. Adolescents (12–19 years) 
with at least one prescription for any SGA and documented activity 540 days pre and 395 
days post index were eligible for this study. Patients who were antipsychotic naïve (no 
evidence of antipsychotic prescription during 540 days pre index period) and 
monotherapy were eligible. The comparison group was stratified randomly matched (3:1) 
to the antipsychotic group based on age, gender, and month of antipsychotic prescription. 
Only those patients with at least one baseline BMI and follow up BMI 90 days post index 
date were eligible for inclusion. A maximum BMI during follow-up was evaluated and 
the percentage change in baseline to follow-up BMI was used as the outcome. 
Multivariate linear regression was used to assess the percent change in follow-up BMI 
from baseline among antipsychotic users compared to the comparison group controlling 
for covariates. Results:  The mean age (15.35 years, SD 2.27) and gender (Males, 53%) 
distribution among the antipsychotic group (n=793) was similar (p>0.05) to the 
comparison group (n=2,373).. The mean percentage increase in BMI from baseline to 
follow-up for all patients with antipsychotic prescription was significantly higher than the 
comparison group (p<0.01) except for ziprasidone (p>0.05). Adolescents on olanzapine 
had the highest percentage increase in BMI from baseline to follow-up (5.84%, 95% 





5.64), risperidone (3.65%; 95% CI, 2.61–4.68), and quetiapine (1.53%; 95% CI, 0.53–
2.52) compared to the comparison group adjusting for covariates. Conclusion: Treatment 
with second generation antipsychotics is associated with significant increase in BMI 
among adolescents relative to a matched comparison group. Monitoring of weight is 





Second generation antipsychotics (SGAs), also known as atypical antipsychotics, 
are prescribed to adolescents in the United States as first line treatment for a variety of 
psychiatric and mood disorders, including but not limited to schizophrenia, bipolar 
disorder, and major depressive disorder.1-4   The Food and Drug Administration (FDA) 
granted pediatric exclusivity for SGAs such as olanzapine, aripiprazole, and risperidone 
in 2007, while quetiapine was approved for pediatric use in 2009. Ziprasidone, another 
SGA, although without pediatric exclusivity is used off label in the pediatric population.5 
Published clinical trials have reported an increased risk of weight gain among both 
preadolescent and adolescent populations, as a result of SGAs.6-9 Although clinical trials 
have addressed the issue of weight gain due to antipsychotic treatment, none have 
compared the individual SGAs to assess the differential impact of weight gain among 
adolescents.  
A recent prospective cohort study conducted in 203 youths aged 4 to 19 years 
with 1 week or less of lifetime antipsychotic treatment assessed the association of SGA 
medications with body composition and metabolic parameters.10 After a median of 10.8 





with olanzapine, by 6.1 kg  with quetiapine, by 5.3kg with risperidone, and by 4.4 kg 
with aripiprazole compared with minimal weight change of 0.2 kg  in the untreated 
comparison group.10 Limitations of this study included the short duration of treatment (12 
weeks), small comparison group (n=20), and limited generalizability of results to the 
national population. The study reported absolute change in body mass index (BMI) from 
baseline to 12 weeks of treatment without adjusting for or matching the comparison 
group to the treatment group by gender. Therefore the study does not account for the 
gender-related difference in BMI.  
Another retrospective cohort study evaluated Medicaid medical and pharmacy 
claims to identify factors associated with incident cardiovascular events and metabolic 
disturbance in children and adolescents treated with antipsychotics.11 The study found 
that antipsychotic treatment was associated with 2.13 times increased likelihood of 
obesity (odds ratio [OR], 2.13), compared to the untreated cohort.11 One of the limitations 
of this study is the limited generalizability of the South Carolina’s Medicaid enrollees to 
the US population as the Medicaid population is usually sicker than the commercially 
insured population.12 The actual impact of antipsychotic treatment on clinical values was 
not known from this study.  
There are limited retrospective comparative effectiveness studies comparing the 
differential risk of weight gain associated with SGAs in the adolescent population. The 
observational studies that have been conducted so far have either used short duration of 
treatment and a small comparison group or conducted studies that cannot be generalizable 
to the national population. A comparative effectiveness study that assesses the differential 





current study is to compare the change in BMI among adolescents within 1 year of 
initiating antipsychotic treatment to the change in BMI among an age- and gender-






The General Electric (GE) Centricity electronic medical record (EMR) database 
was used for this study. The GE EMR database includes approximately ten million 
patients and is comprised of data collected during routine use of the EMR by more than 
70 consortium member institutions located in more than 40 states. The GE Centricity is 
an EMR system that enables ambulatory care physicians and clinical staff to document 
patient encounters, streamline clinical workflow, and securely exchange clinical data with 
other providers, patients, and information systems. Centricity EMR is used by more than 
20,000 clinicians to manage about 30 million patient records in 42 states, making it a 
widely used ambulatory care EMR. This EMR system replaces the paper medical record 
for the patients in the participating medical offices. A variety of practice types are 
represented ranging from solo practitioners to community clinics, to academic medical 
centers, and large integrated delivery networks. The resulting research database provides 
information reflective of the clinical data captured in the practice setting, including 
diagnoses, chief complaints, medication orders, medication lists (patient-reported 
prescription and over-the-counter drug use), laboratory orders and results, and biometric 





the data and remove invalid values. The EMR database is de-identified, HIPAA 





A retrospective cohort study design was used for this study. The retrospective 
cohort consisted of adolescents 12-19 years old. Within this cohort, adolescents with any 
prescription for second-generation antipsychotics were considered as the exposed group 
while nonprescribed adolescents were considered as the unexposed or the comparison 





Patients in the exposure group were eligible for inclusion in this study if they 1) 
were 12–19 years old and, 2) had at least one prescription for any SGA between January 
2004 and July 2009 and, 3) had at least one documented physician visit ≥540 days before 
the index date (defined below) and at least one documented physician visit ≥ 395 days 
after the index date and, and 4) had no prescription for any antipsychotic agent during the 
540 days before the index date (Figure 1). Patients in the exposure group were assigned 
an index date which was their first prescription for antipsychotic medication and were 
categorized as exposed to individual SGAs depending on the type of their index 
antipsychotic prescription. We limited the analysis to antipsychotic naïve patients (i.e., no 
prescription during the pre index period of 540 days) to increase the chances of 





same antipsychotic agent as the index antipsychotic agent throughout the follow-up 
period, defined as monotherapy, were included in this study. Small proportions of 
exposed patients (10%) switched medications or were prescribed multiple antipsychotics 
during the follow up period and were excluded from this study. 
The comparison population was identified based on presence of an activity 
(medical visit or prescription) in the GE EMR database and no prescriptions for any 
SGA. Patients in the comparison group were eligible for inclusion in this study if they 1) 
were 12–19 years old and, 2) had no prescription for any antipsychotic agent between 
January 2004 and July 2009 and, 3) had at least one documented physician visit ≥540 
days before the index date and at least one documented physician visit ≥395 days after 
the index date. 
Both the exposure and comparison group were followed for a period of 395 days 
from the date of index prescription or activity defined as the follow-up period. A follow-
up period of 395 days was used to account for any gaps in therapy and to allow 30 days 
follow-up period for antipsychotic prescriptions prescribed closest to the 365th day. We 
restricted analysis to patients with a documented physician visit at least 540 days before 
index date and at least one documented physician visit 395 days after index date. This 
was done to ensure that patients were active participants in the healthcare system and 
were regularly visiting the physician during this period. This methodology has been 
applied in previous publications based on the GE database.13-15 The final comparison 
group population consisted of individuals who were matched (3:1) to the antipsychotic 






The EMR was examined for the presence of baseline and follow up BMI 
measurements. Baseline BMI measurements were defined as those that occurred in the 30 
days before the index date. BMI measurements that occurred 90 days post index date 
through the end of follow-up period were categorized as follow up measurements. Only 
those patients with baseline and at least one follow up BMI measurement were included 
in the analysis. An average of baseline values was taken if more than one existed during 
the 30-day period. Follow-up BMI measurements were categorized to each month 
depending on the date of BMI measurement and number of days from index date. An 
average of BMI values was taken if more than one BMI measurement was present in a 
particular month. The maximum BMI value during the follow-up period was identified 
and the mean difference and percentage change in baseline to maximum follow-up BMI 
was calculated. Excess weight for children and adolescents is defined based on the year 
2000 CDC gender-specific BMI-for-age growth charts.16 Children and adolescents with 
BMI <5th percentile are considered underweight, 5th to 85th percentile are normal weight, 
85th to 95th percentile are considered overweight and those at and beyond the 95th 
percentile are considered obese.17 Gender specific growth charts were used to categorize 
patients as underweight, normal weight, overweight, or obese at baseline and at follow-
up. 
Demographic characteristics such as age and gender, region, insurance type, 
medications, and baseline medical conditions were identified during the pre index period. 
Insurance type and geographic region (Northeast, Southeast, Midwest, and West) were 
identified to examine the baseline differences by insurance type and regional variation. 





antidiabetic agents that cause weight gain (such as human insulin, sulphonylureas, and 
thiazolidinediones) or weight loss (such as incretin mimetic agents and biguanides), 
antidepressants, anticonvulsants, and corticosteroids were identified among all patients 
using prescription orders during the pre index period.  Baseline medical conditions that 
may influence BMI such as dyslipidemia, hypertension, obesity, hypothyroidism, and 
type 2 diabetes; psychiatric conditions such as schizophrenia, depression, bipolar 
disorder, and other mental illness; and miscellaneous diagnosis were identified using 
ICD-9 codes during the pre index period. Mental illness encompassed psychoses, 
neurotic disorders, personality disorders, other nonpsychotic mental disorders, and mental 
retardation.  Miscellaneous diagnoses included general symptoms, symptoms involving 
nervous and musculoskeletal systems, respiratory, head and neck, cardiovascular, 
digestive, urinary, nonspecific abnormal finding, and ill-defined and unknown causes of 





Test of proportions was used to evaluate the differences in baseline demographics, 
baseline medications, and baseline medical conditions between the exposed and 
comparison groups. Student’s t test with unequal variances was used to evaluate the 
differences in age, baseline BMI, maximum follow-up BMI, mean difference and 
percentage change in baseline to follow-up BMI between the exposed and comparison 
groups. Test of proportions was used to evaluate the differences in proportion of 
underweight, normal weight, overweight, and obese at baseline and follow-up. 





exposure on percentage change in maximum follow-up BMI from baseline BMI 
controlling for demographic characteristics, baseline BMI, baseline medications, baseline 
baseline medical conditions, number of follow-up BMI measurements, number of months 
to maximum follow-up BMI, and year of index prescription. Analyses were performed 
using SAS Version 9.2 (SAS Institute, Cary, NC) and STATA Version 10.0 (StataCorp. 
2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP). This 
study was approved by the institutional review board at the University of Utah on 





  A total of 7,967 adolescents with at least one prescription for SGAs and 669,207 
adolescents without SGAs while were identified in the GE EMR database between 
January 2004 and July 2009 (Figure 7). Of those on SGAs, 3,039 patients had at least one 
documented physician visit ≥540 days before index date and at least one documented 
physician visit ≥395 days after index date. Of these, 2,295 patients had no evidence of 
antipsychotic prescription 540 days before index date and were on monotherapy during 
395 days after index prescription. Of these, 1,731 patients had at least one baseline BMI 
in the 30 days prior to index antipsychotic prescription. The final exposed group 
consisted of 793 patients with at least one BMI recorded at 90 days or more following 
their index antipsychotic prescription. Of those without SGAs, 172,207 patients had at 
least one documented physician visit ≥540 days before index date and at least one 
documented physician visit ≥395 days after index date. Further, only those patients with 





index date were included. The final comparison group consisted of 2,374 randomly 
selected patients matched to the antipsychotic group based on gender, age, and month of 




Demographics and medical conditions 
 Table 10 presents the demographics, medication use, and baseline medical 
conditions among the exposed and comparison group. The mean age (15.35 years; SD 
2.27) and gender distribution (53% males) were similar among the antipsychotic group 
and the comparison group (p>0.05) which was as expected because of the matched 
selection strategy. The antipsychotic group had significantly higher proportion of patients 
from the Northeast, Southeast, Medicare, and Medicaid insurance (p<0.01). Also, the 
antipsychotic group had significantly higher proportion of patients with baseline 





Baseline and follow-up BMI values in exposed  
and comparison group 
 Table 11 presents the summary statistics for the baseline and follow-up BMI 
values among the comparison group, antipsychotic group, and antipsychotic group 
stratified by individual antipsychotic agents. Overall, the exposure group had 
significantly higher mean baseline BMI, follow-up BMI, mean difference, and percent 





significantly shorter, and the numbers of BMI measurements were greater in the exposed 
group compared to the group not prescribed SGAs.   
Among the individual antipsychotic agents, the mean baseline BMI among 
patients on olanzapine and risperidone was similar to the comparison group (p>0.05). 
However, patients on ziprasidone, aripiprazole, and quetiapine had higher baseline BMI 
compared to the group not prescribed SGAs. Adolescents on individual antipsychotic 
agents had a significant percentage increase (p<0.01) in follow-up BMI from baseline 
except for patients prescribed ziprasidone where the percentage increase was not 
significant (p=0.211) compared to those not prescribed SGAs. Although, the baseline 
BMI in adolescents on olanzapine was similar to the comparison group the mean 
percentage increase from baseline to follow-up BMI was highest for patients prescribed 
olanzapine (8.50%). Adolescents on aripiprazole (7.88%), risperidone (7.34%), and 
quetiapine (5.02%) had relatively lesser percentage increase in baseline to follow up BMI 
than olanzapine but significantly higher compared to those not prescribed SGAs. BMI 
was measured more often in adolescents on individual antipsychotics with significantly 
higher mean number of BMI measurements (p<0.01) during the follow-up period except 
for olanzapine. The mean number of BMI measurement among adolescents on olanzapine 
was not statistically different from the comparison group. The time in months to required 
to attain maximum follow-up BMI was shorter (p<0.01) for adolescents on individual 








Linear regression results   
 Table 12 presents the adjusted linear regression coefficients for percent change in 
BMI from baseline to follow-up among adolescents on individual antipsychotic agents 
compared to the group not prescribed SGAs adjusting for demographic characteristics, 
baseline medications, baseline medical conditions, year of index date, number of follow-
up BMI measurements, and time in months to maximum follow-up BMI. Adolescents on 
olanzapine had the highest percentage increase in BMI during the 395-day follow-up 
period (5.84%, 95% confidence interval [CI], 4.07–7.61). Patients on aripiprazole had 
4.36% (95% CI, 3.08–5.64) followed by risperidone (3.65%; 95% CI, 2.61–4.68), and 
quetiapine (1.53%; 95% CI, 0.53–2.52) compared to the comparison group. The small 
number of adolescents on ziprasidone did not show a statistically significant change in 
BMI.  
Baseline BMI was significantly associated with percentage change in baseline to 
follow-up BMI. Although not statistically significant, adolescents who were underweight 
had a 1.2% increase in baseline to follow-up BMI compared to normal weight 
adolescents. However, adolescents who were normal weight gained more weight 
compared to overweight and obese adolescents. Normal weight adolescents had   0.96% 
increase in baseline to follow- up compared to overweight and 1.42% increase in follow-
up BMI compared to obese adolescents. As age increased from 12 to 19 years the 
percentage change from baseline to follow-up BMI decreased by 0.33% for each year. 
Gender, region, insurance status, baseline medications, and baseline medical conditions 








The purpose of the study was to assess the association of SGAs with changes in 
BMI among adolescents compared to a stratified random age and gender matched 
untreated comparison group. Prescription of olanzapine, aripiprazole, risperidone, and 
quetiapine was associated with significant changes in BMI after initiating antipsychotic 
treatment compared to the untreated comparison group. Only adolescents prescribed 
ziprasidone did not show significant changes in BMI compared to the untreated 
comparison group. This is likely due to the small sample size of patients on ziprasidone 
which may not be enough to detect a statistically significant difference. Patients 
prescribed quetiapine had the lowest percentage change in follow-up BMI from baseline 
BMI compared to the comparison group and those on other antipsychotics.  
The results indicate that adolescents on antipsychotics gained more weight in a 
shorter duration of time compared to the comparison group. Adolescents on 
antipsychotics gained 7% of baseline BMI in 8 months of initiating antipsychotic 
treatment while the comparison group gained 3% of baseline BMI in 9 months. The 
results of this study were consistent with the previously discussed prospective cohort 
study where olanzapine, aripiprazole, risperidone, and quetiapine were associated with 
significant increases in weight among adolescents.10    
The public health implications of adolescent patients on antipsychotic drugs and 
its associated cardiometabolic adverse effects are substantial. At present obesity is a 
serious health concern among all adolescents. Weight gain as a result of antipsychotic 
medications may cause further problems in these adolescents since their self-esteem may 





Weight gain is not only an issue of self-esteem; it is also associated with long term health 
risks of obesity, type 2 diabetes, hyperlipidemia, and hypertension.18 Children and 
adolescents who are obese are more likely to become obese adults. A study published by 
Whitaker et al. found that approximately 80% of children who were overweight at age 
10–15 years were obese adults at age 25 years.19 In addition, childhood obesity is 
associated with adult cardiovascular adverse outcomes and impaired glucose tolerance.20-
23 If weight gain among adolescents on antipsychotics is not controlled, it may result in 
high burden and increased use limited health resources to treat obesity-related diseases in 
addition to mental health issues when these adolescents become adults. Also, obesity and 
mental illness may result in serious consequences on the quality of life of adolescents. 
Interestingly, normal weight adolescents on antipsychotics gained proportionally 
more during the follow-up period compared to the overweight and obese adolescents. 
Physicians may be more aggressively monitoring weight and taking steps to decrease 
weight gain in the overweight and obese adolescents on antipsychotics than their normal 
weight counterparts. It is important to monitor BMI systematically in overweight and 
obese adolescents on antipsychotics. However, it is equally important to monitor and 
control BMI in normal weight adolescents on antipsychotics using weight management 
strategies after initiating antipsychotic treatment to prevent transitioning from normal 
weight to overweight or obese.  
The American Diabetes Association (ADA)/ American Psychiatric Association 
(APA) guidelines, published in February 2004, recommend monitoring of metabolic 
parameters such as weight and body mass index (BMI), blood pressure, fasting plasma 





regardless of age.24 According to the guidelines, BMI should be monitored at least 4 
times within 90 days and 3 times post 90 days of initiating antipsychotic treatment.  In 
this study, adolescents on antipsychotics nearly met the guidelines for BMI monitoring 
with slightly less than 3 BMI measurements post 90 days of initiating antipsychotic 
treatment. The SGA group had significantly more BMI measurements compared to the 
group not prescribed SGA. There was heterogeneity by individual SGA, however. 
Adolescents prescribed olanzapine had the lowest number of BMI measurements among 
adolescents prescribed SGA. Their BMI monitoring was not significantly different from 
the untreated comparison group’s even though olanzapine treatment is associated with the 
highest risk of weight gain and metabolic changes among the SGAs.10 Physicians treating 
adolescents with antipsychotics need to be familiar with treatment guidelines and review 
the weight gain potential associated with antipsychotic agents and regularly monitor 
adolescents to avoid the long term risks. 
In this study, almost half of the adolescents with prescription for SGAs were from 
the South US. This is consistent with previous studies where the proportion of overweight 
adolescents and children from the South was the highest.25, 26 As expected, we observed a 
higher proportion of adolescents on antipsychotics had commercial insurance followed by 
Medicaid. Almost 55% of U.S. children have employer based health insurance while 
Medicaid along with other state programs cover 29% of U.S. children.27 However, the 
proportion of adolescents with Medicaid insurance was significantly higher among 
antipsychotic users than nonantipsychotic users (p<0.01). Medicaid youths are 4 times as 





insurance.26-28 and antipsychotic prescribing has increased considerably in adolescents 
with Medicaid insurance.28  
The primary strength of this study is that actual clinical measures such as BMI 
values in the GE EMR database were used to assess change in weight among adolescents 
on antipsychotics. Previous studies have used current ICD-9 codes and not actual clinical 
measures to assess obesity/weight gain in adolescents on antipsychotics11 which may 
have resulted in reporting conservative estimates. ICD-9 codes for obesity are not 
frequently used, and patients who became obese after antipsychotic treatment may have 
been missed. Also, ICD-9 codes define obesity as BMI above 30kg/m2 which may not 
apply to adolescents where overweight and obesity is defined based on BMI percentiles 
compiled on growth charts from the Centers for Disease Control and Prevention.16 
Another strength of the study is the use of a national population and age and gender 
matched stratified random comparison group. Previous study has reported absolute 
change in body mass index (BMI) without adjusting for or matching the comparison 
group to the treatment group by gender and therefore did not account for gender-related 
differences in BMI.   
As with any research study there are several limitations. One of the most 
important limitations of this study is that prescriptions in an EMR database are tracked by 
prescription orders and medication lists and not by actual prescriptions filled at the 
pharmacy. We cannot be entirely sure if patients are filling and taking medications 
prescribed to them. Due to this limitation misclassification of exposure may occur. 
Patients with at least one prescription order for a SGA were considered to be on the drug 





antipsychotic users even if the drug was not taken throughout the follow up period and 
creating a bias toward no effect of the drug upon weight. Another limitation of the 
database is that it is predominantly a primary care physician network and, therefore, 
health care received outside of the primary care setting may not be captured in the 
database. We are probably studying antipsychotic users who are relatively less sick 
compared to those patients seeking care from psychiatrists.  However, an increasing 
number of primary care physicians are prescribing antipsychotic drugs to children on the 
front line when it comes to diagnosing and treating mental disorders. Almost 85% of all 
prescription for psychotropic medications are prescribed by primary care physicians and 
pediatricians.29  
Missing BMI values in the GE EMR database are another limitation for this study, 
but we have no evidence that inclusion of BMI values are associated with SGA 
prescription and assume that the bias is nondifferential. Another limitation of this study is 
that the comparison group was identified based on their index activity in the GE EMR 
database. This may have resulted in a selection bias and the comparison group patients 
may be monitored more often during their initial visits to the physician. However, a 6-
month preindex period was used which may have accounted for this bias. Finally, the 
database lacks information on socioeconomic status, diet, physical activity, or overall 
health of patient’s parents. These unmeasured variables, among other variables, play a 
significant role in impacting the weight of adolescents in the data.  
A small proportion of patients on antipsychotics (10%) switched medications or 
were on multiple antipsychotics in this study. Adolescents on antipsychotics in 





antipsychotic agent. Due to small sample size, this group was excluded from the analysis 





Second generation antipsychotic treatment in adolescents is associated with 
significant increase in BMI relative to a matched comparison group. Aggressive 
monitoring of weight is recommended among adolescents treated with antipsychotics and 
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Figure 7 Schematic of Study Design 
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Figure 8 Flowchart of Patient Selection  
 




Patients 12–19 years with at least one 
activity without a prescription for 
antipsychotics 
n=669,207 
Patients with at least 1 documented 
physician visit ≥540 days before 
index date and at least one 
documented physician visit ≥395 
days after index date  
n=172,207 
Patients with at least one baseline 
BMI in 30 days prior and at least one 
follow-up BMI 90 days post index 
date 
n=59,315 
Final comparison group sample 
n=2,373 
Age and gender stratified random 
sampling using 3:1 matching to final 
exposed group 
Patients 12–19 years with at least one 
prescription for SGA 
n=7,967 
Patients with at least 1 documented 
physician visit ≥540 days before index 
date and at least one documented 




Patients with no evidence of 
antipsychotic prescription 540 days 
before index date and on monotherapy 
during 395 days follow-up period  
n=2,295 
Exposure Group Comparison Group 
Patients with at least one baseline BMI 
in 30 days prior to index date  
n=1,731 
 
Final exposed group with at least one 






Table 10 Demographics, Medication Use, and Medical Conditions in Exposed and 
Comparison Group Adolescents, 2004 to 2009 
  
  
Comparison Group    Exposure Group P Value  
  n=2,373 n=793 
n % n  % 
Mean Age (SD) 15.35 (2.27) 15.35 (2.28) 0.928 
Gender          
Males 1248 52.59 418 52.71 0.953 
Females 1125 47.41 375 47.29 0.953 
Region          
Northeast 436 18.37 197 24.84 <0.001 
Southeast 823 34.68 371 46.78 0.006 
Midwest 453 19.09 117 14.75 <0.001 
West 661 27.86 108 13.62 <0.001 
Insurance Type          
Commercial 1159 48.84 370 46.66 0.287 
Medicaid 119 5.01 145 18.28 <0.001 
Medicare 3 0.13 10 1.26 <0.001 
Self-pay 46 1.94 12 1.51 0.440 
Other/Unknown 1046 44.08 256 32.28 <0.001 
Baseline 
Medications 
         
Beta Blockers 0 0.00 14 1.77 <0.001 
Oral 
Antidiabetics 
3 0.13 15 1.89 <0.001 
Antidepressants 2 0.08 30 3.78 <0.001 
Anticonvulsants  0 0 62 7.82 <0.001 




         
Dyslipidemia 25 1.05 13 1.64 0.190 
Hypertension 4 0.17 6 0.76 0.011 
Obesity 72 3.03 63 7.94 0.011 
Hypothyroidism 6 0.25 8 1.01 <0.001 
Psychiatric 
Conditions 
    
 
Schizophrenia 0 0.00 4 0.50 <0.001 
Bipolar Disorder 9 0.38 66 8.32 <0.001 
Depression 4 0.17 31 3.91 <0.001 
Type 2 Diabetes 7 0.29 56 7.06 <0.001 
Other 
Conditions 




285 12.01 299 37.70 
0.000 
Mental Illness^ 167 7.04 379 47.79 0.000 
*Miscellaneous Diagnosis consists of ICD-9 codes 780 to 799, ^ Mental Illness was identified using ICD-9 





Table 11 Summary Statistics for Baseline and Follow up BMI Values among Exposed and Comparison Group Adolescents, 
2004 to 2009 






Antipsychotic Group N=793 
Aripiprazole Olanzapine Risperidone Quetiapine Ziprasidone 
 N= 158 N=74 N=255 N=286 N= 20 
N N% N N% N N% N N% N N% N N% N N% 
Mean Baseline 
BMI (SD) 
23.81 (5.23) 24.68 (6.41)^ 26.09 (6.88)^ 24.51 (6.15) 23.21 (5.80) 24.95 (6.35)^ 29.08 (7.32)^ 
Underweight a  40 1.69 29 3.66^ 2 1.27 6 8.11^ 11 4.31^ 10 3.50* 0 0.00 
Normal Weight b  1,473 62.07 429 54.1^ 78 49.37^ 40 54.05 150 58.82 154 53.85^ 7 35.00* 
Overweight c  407 17.15 123 15.51 18 11.39 11 14.86 44 17.25 48 16.78 2 10.00 
Obese d   453 19.09 212 26.73^ 60 37.97^ 17 22.97 50 19.61 74 25.87^ 11 55.00^ 
Mean Follow-up 
BMI (SD) 
24.57 (5.44) 26.25 (6.88) ^ 28.01 (7.29)^ 26.60 (7.09)^ 24.82 (6.13) 26.20 (6.95)^ 29.93 (6.94)^ 
Underweight  19 0.8 14 1.77^ 2 1.27 3 4.05^ 1 0.39 8 2.80^ 0 0.00 
Normal Weight  1,362 57.4 375 47.29^ 61 38.61^ 33 44.59* 135 52.94 141 49.30^ 5 25.00^ 
Overweight 468 19.72 140 17.65 22 13.92 15 20.27 55 21.57 44 15.38 4 20.00 
Obese   524 22.08 264 33.29^ 73 46.20^ 23 31.08 64 25.10 93 32.52 11 55.00^ 
Mean Difference 
(Baseline to Max 
Follow-up BMI) 
(SD) 
0.76(1.72) 1.57(2.26) ^ 1.93(2.68)^ 2.09 (2.42)^ 1.61 (2.03)^ 1.25 (2.04)^ 0.85 (2.95) 
Mean Percentage 
Increase (Baseline to 
Max Follow-up 
BMI) (SD) 
3.40 (6.95) 6.63 (9.07)^ 7.88 (10.40)^ 8.50 (9.57)^ 7.34 (9.03)^ 5.02 (7.69)^ 3.97 (11.25) 
Mean Follow-up 
time to Max BMI 
(months) (SD) 
8.83 (2.39) 7.99 (2.92)^ 7.99 (2.98)^ 7.55 (3.04)^ 8.17 (2.88)^ 7.93 (2.85)^ 8.00 (3.58) 
Mean No. of BMI 
Measurements Post 
90 Days Index Rx 
(SD) 
2.08 (1.34) 2.70 (1.71)^ 2.96 (1.87)^ 2.35 (1.74) 2.47 (1.45)^ 2.83 (1.77) ^ 3.00 (2.15)^ 
^p<0.01, *p<0.05. Test of proportions were used to compare the individual antipsychotics to the comparison group. a Underweight: BMI<5th Percentile; 







Table 12 Adjusted Linear Regression Coefficients for Percentage Change in Baseline to 
Maximum Follow-up BMI in Adolescents from 2004 to 2009 
 Adjusted 
Coefficients* 
95% CI P value 
Baseline BMI     
Normal Weight 
(<85th Percentile) 
ref    
Underweight 
(<5th Percentile) 
1.20 -0.57 2.96 0.184 
Overweight 
(≥85th to <95th Percentile) 




-1.41 -2.07 -0.74 <0.001 
Treatment     
Comparison Group ref    
Aripiprazole 4.36 3.08 5.64 <0.001 
Olanzapine 5.84 4.07 7.61 <0.001 
Risperidone 3.65 2.61 4.68 <0.001 
Quetiapine 1.53 0.53 2.52 0.003 
Ziprasidone 
 
0.99 -2.32 4.30 0.559 
Gender     
Males ref    
Females 
 
-0.25 -0.78 0.29 0.364 
Age in Years 
 
-0.33 -0.45 -0.21 <0.001 
Region     
Northeast ref    
Midwest 0.16 -0.56 0.88 0.664 
South -0.29 -1.13 0.55 0.501 
West 
 
-0.09 -0.88 0.71 0.828 
Insurance     
Commercial ref    
Medicaid -0.65 -1.62 0.33 0.194 
Medicare -3.37 -7.42 0.68 0.103 
Self Pay -0.37 -2.29 1.56 0.710 
Unknown 0.18 -0.39 0.75 0.535 
*Adjusted for baseline medications, baseline medical conditions, psychiatric conditions, other conditions, 
number of follow-up BMI values, year of index prescription or activity, and number of months to 
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The purpose of the study described in Chapter II was to assess the overall and 
quarterly trends of prevalence of overweight and obesity in adolescents on antipsychotics 
compared to a stratified random matched comparison group from 2000 to 2009. The 
hypothesis of this study was that increase in the prevalence of antipsychotic use increases 
the prevalence of overweight among adolescents on antipsychotics compared to those not 
treated with antipsychotics overall and across time. Overall, the prevalence of overweight 
and obese from 2000 to 2009 was found to be higher among male and female 
antipsychotic users compared to the male and female comparison group, respectively. 
However, the trend of overweight and obese adolescent male antipsychotic users 
decreased while the trend of overweight and obese nonantipsychotic user males increased 
from 2000 to 2009. The decreasing trend in male antipsychotic users may be associated 
with better management of excessive weight gain or use of antipsychotics with lower 
potential for weight gain or related to hormonal differences among male and female 
adolescents. Contrary to males, the trend in the prevalence of overweight and obese in 






remained unchanged from 2000 to 2009. The trend of prevalence of overweight and 
obese among the female comparison group remained stable and did not show statistically 
significant change.  Antipsychotic treatment may have differential impact on weight gain 
in adolescent males and females or a disparity in monitoring metabolic parameters may 
exist between adolescent males and females. More research is needed that assesses the 
weight gain potential of antipsychotic treatment among adolescent males and females 
separately. Also, future studies should assess the monitoring patterns of metabolic 
parameters in adolescents treated with antipsychotics to assess if any disparity exists in 
monitoring metabolic parameters among males and females. The public health 
implications of overweight and obesity among children and adolescents in the United 
States are significant. Weight gain among adolescents may be associated with long term 
health risks of obesity, dyslipidemia, diabetes, and hypertension. If weight gain among 
adolescents on antipsychotics is not controlled, it may result in high burden and increased 
use of limited health resources to treat obesity-related diseases in addition to mental 
health issues when these adolescents become adults.  
The ADA/APA guidelines recommend regular monitoring of metabolic 
parameters in adolescents treated with antipsychotics. In the study described in Chapter 
III we assessed the frequency of regular monitoring of metabolic parameters as 
recommended by ADA/APA guidelines among adolescents with prescription for SGA 
compared to an untreated cohort in a predominantly primary care setting. Also, based on 
the conclusion from study in Chapter II we wanted to assess if a disparity in monitoring 
metabolic parameters exists between adolescent males and females. Overall, 55% of the 






BMI, and approximately 2% for lipids and glucose compared to 9.46%, 7.43%, 0.76%, 
and 0.71% respectively in the comparison group as recommended by ADA/APA 
guidelines in this study. The frequency of regular monitoring observed in this study was 
higher for adolescents on antipsychotics than the untreated comparison group. However, 
the incremental difference in the frequency of monitoring among the exposed and 
unexposed was extremely low. Specifically, the monitoring of lipids and glucose was less 
than 1% higher among adolescents with prescription for antipsychotics compared to the 
untreated cohort. Most importantly, less than 1% of exposed patients experienced 
monitoring of all four metabolic parameters as suggested by the guidelines which were 
not significantly different than the untreated comparison group. This study demonstrated 
that relatively fewer numbers of adolescents with prescription for antipsychotics were 
being monitored regularly by clinicians who are treating them. Overall, the likelihood of 
monitoring metabolic parameters, as recommended by the ADA/APA guidelines 
published in February 2004, increased each year from the year 2004 onwards. Although, 
the frequency of monitoring of metabolic parameters is lower than expected, the results 
indicate that the guidelines were being put into practice gradually. Antipsychotic 
treatment in adolescents was associated with increased monitoring of metabolic 
parameters. However, no differences were observed in the likelihood of regular 
monitoring of metabolic parameters across individual SGAs with the exception of fasting 
blood glucose. Adolescents on olanzapine or ziprasidone were being monitored regularly 
for fasting blood glucose while no differences were observed in the likelihood of regular 
monitoring among other SGAs compared to the comparison group. Even though 






monitoring of metabolic parameters as recommended by ADA/APA guidelines among 
adolescents on antipsychotics was low. Also, the likelihood of metabolic monitoring 
among females was higher and lower in some instances compared to males. The strongest 
predictors of regular monitoring of BMI were oral antidiabetic use and new diagnosis of 
type 2 diabetes. Both of these were stronger predictors of BMI monitoring than 
antipsychotic use.  Preexisting and new diagnosis of dyslipidemia was found to be the 
strongest predictor of metabolic monitoring of blood pressure, total cholesterol, and 
fasting blood glucose with higher likelihood of regular monitoring than antipsychotic use. 
Although antipsychotic use was not the strongest predictor of metabolic monitoring, 
adolescents on antipsychotics with preexisting conditions had higher likelihood of 
metabolic monitoring compared to the comparison group with preexisting conditions. 
However, the likelihood of regular monitoring among adolescents on antipsychotics 
without preexisting metabolic conditions was lower compared to those with preexisting 
conditions. Adolescents on antipsychotics are not being monitored according to 
guidelines published by the ADA/APA although their metabolic parameters are being 
monitored modestly more frequently than age and gender matched comparison group. In 
particular, the majority of adolescents treated with antipsychotics remain under 
monitored for BMI, lipids, and glucose as recommended by the ADA/APA guidelines. 
Antipsychotic users with preexisting and newly diagnosed metabolic conditions were 
most likely to be regularly monitored than antipsychotic users without such conditions. 
Without regular monitoring of metabolic parameters, adolescents on antipsychotics may 
be more likely to grow into adulthood with abnormal weight and other metabolic 






increase awareness and adherence to ADA/APA guidelines in monitoring metabolic 
parameters among primary care physicians need to be developed. Clinicians need to be 
more proactive in monitoring metabolic parameters among all adolescents receiving 
antipsychotics prescriptions and not just those with preexisting metabolic conditions. 
Future studies should survey primary care providers to ascertain the challenges associated 
with monitoring of metabolic parameters among adolescents. 
The purpose of the study described in Chapter IV was to assess the association of 
SGAs with changes in BMI among adolescents compared to a stratified random age and 
gender matched untreated comparison group. Prescription of olanzapine, aripiprazole, 
risperidone, and quetiapine was associated with significant changes in BMI after 
initiating antipsychotic treatment compared to the untreated comparison group. Only 
adolescents prescribed ziprasidone did not show significant changes in BMI compared to 
the untreated comparison group. Patients prescribed quetiapine had the lowest percentage 
change in follow-up BMI from baseline BMI compared to the comparison group and 
those on other antipsychotics. The results indicate that adolescents on antipsychotics 
gained more weight in a shorter duration of time compared to the comparison group. 
Adolescents on antipsychotics gained 7% of baseline BMI in 8 months of initiating 
antipsychotic treatment while the comparison group gained 3% of baseline BMI in 9 
months. Interestingly, normal weight adolescents on antipsychotics gained proportionally 
more during the follow-up period compared to the overweight and obese adolescents. In 
this study, adolescents on antipsychotics nearly met the ADA/APA guidelines for BMI 
monitoring with slightly less than 3 BMI measurements post 90 days of initiating 






compared to the group not prescribed SGA. There was heterogeneity by individual SGA, 
however. Adolescents prescribed olanzapine had the lowest number of BMI 
measurements among adolescents prescribed SGA. Their BMI monitoring was not 
significantly different from the untreated comparison groups even though olanzapine 
treatment is associated with the highest risk of weight gain and metabolic changes among 
the SGAs. In this study, almost half of the adolescents with prescription for SGAs were 
from the South US. As expected, we observed a higher proportion of adolescents on 
antipsychotics had commercial insurance followed by Medicaid. Second generation 
antipsychotic treatment in adolescents is associated with significant increase in BMI 
relative to a matched comparison group. Aggressive monitoring of weight is 
recommended among adolescents treated with antipsychotics and promoted in 
professional treatment guidelines such as those from the ADA/APA. The public health 
implications of adolescent patients on antipsychotic drugs and its associated 
cardiometabolic adverse effects are substantial. At present obesity is a serious health 
concern among all adolescents. Weight gain as a result of antipsychotic medications may 
cause further problems in these adolescents since their self-esteem may already be low 
due to coping with their mental illness and weight gain can make it worse. If weight gain 
among adolescents on antipsychotics is not controlled, it may result in high burden and 
increased use limited health resources to treat obesity-related diseases in addition to 
mental health issues when these adolescents become adults. Also, obesity and mental 
illness may result in serious consequences on the quality of life of adolescents. 
In conclusion, the likelihood of metabolic monitoring among females was higher 






gain were found after initiating antipsychotic treatment between adolescent males and 
females. This study was not able to assess if disparity in monitoring metabolic parameters 
existed between males and females. Future research should focus on metabolic 
monitoring in males and females on antipsychotics to assess if any disparity exists in 
monitoring metabolic parameters between males and females. In the current study we 
were only able to assess few predictors of metabolic monitoring among adolescents on 
antipsychotics due to limitations of the dataset used. This study was not able to determine 
the reasons for low monitoring of metabolic parameters among adolescents. Future 
studies should focus on determining the reasons for low monitoring by surveying primary 
care providers to ascertain the challenges associated with monitoring of metabolic 
parameters among adolescents. Without regular monitoring of metabolic parameters, 
adolescents on antipsychotics are at higher risk of growing into adulthood with abnormal 
weight and other metabolic parameters that impact adult obesity and its cardiovascular 
outcomes. More research is needed that assesses the weight gain potential of 
antipsychotic treatment among adolescent males and females separately. 
 
